[COMPANY_001] Research and Development  
AIN457 
Clinical Trial Protocol CAIN457P12301 / [STUDY_ID_REMOVED] 
A randomized, double -blind, placebo -controlled, parallel 
group, phase III multicente r study of intravenous 
secukinumab t o compare efficac y at 16 weeks w ith placebo 
and to assess safety and tolerability up to 52 weeks in 
subjects with active Ankylosing Spondylitis or non -
radiographic axial SpondyloArthritis 
Document type:  Clinical Trial Protocol  
EUDRACT number:  2019 -001177 -90 
Version number:  00 (Original Protocol)  
Clinical Trial Phase:  III 
Release date:  16-Aug-2019
Property of [COMPANY_001]/sponsor  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 2.0 dated 01 -Aug-2018  
[COMPANY_001]  Confidential  Page 2 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Table of contents  
Table of contents ................................................................................................................. [ADDRESS_1027632] of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 11 
Protocol summary  .............................................................................................................. 13 
1 Introduction ....................................................................................................................... 20 
1.1 Background ............................................................................................................ 20 
1.2 Purpose .................................................................................................................. 21 
2 Objectives and endpoints ................................................................................................... 21 
3 Study design ...................................................................................................................... 26 
4 Rationale ............................................................................................................................ 28 
4.1 Rationale for study design ..................................................................................... 28 
4.1.1 Rationale for choice of background therapy ......................................... 28 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 29 
4.3 Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 29 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 30 
4.5 Risks and benefits .................................................................................................. 30 
5 Population .......................................................................................................................... 31 
5.1 Inclusion criteria  .................................................................................................... 32 
5.2 Exclusion criteria  ................................................................................................... 33 
6 Treatment  ........................................................................................................................... 35 
6.1 Study treatment ...................................................................................................... 35 
6.1.1 Investigational and control drugs .......................................................... 35 
6.1.2 Additional study treatments .................................................................. 36 
6.1.3 Treatment arms/group  ........................................................................... 36 
6.1.4 Treatment duration  ................................................................................ 36 
6.2 Other treatment(s)  .................................................................................................. [ADDRESS_1027633] numbering ................................................................................ 40 
6.3.2 Treatment assignment, randomization  .................................................. 40 
6.4 Treatment blinding  ................................................................................................ 41 
[COMPANY_001]  Confidential  Page 3 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
6.[ADDRESS_1027634] demographics/other baseline characteristics............................................. 53 
8.3 Efficacy  .................................................................................................................. 53 
8.3.1 Assessment of SpondyloArthritis International Society criteria 
(ASAS)  .................................................................................................. 54 
8.3.2 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ........ 55 
  55 
8.3.4 Bath Ankylosing Spondylitis Functional Index (BASFI) ..................... 55 
8.3.5 Patient’s global assessment of disease activity (VAS)  ......................... 55 
8.3.6 Patient’s assessment of back pain intensity (VAS)  ............................... 55 
  56 
8.3.8 Medical Outcome Short Form Health Survey (SF- 36) Version 2 
(Acute Form)  ......................................................................................... 56 
8.3.9 Ankylosing Spondylitis Quality of Life (ASQoL) ................................ 56 
8.3.10 High Sensitivity C- reactive protein (hsCRP)  ........................................ 57 
  57 
 
 57 
8.3.13 ASDAS -CRP and ASDAS response categories  .................................... 57 
 
 57 
  58 
8.3.16 Sleep improvement................................................................................ 59 

[COMPANY_001]  Confidential  Page 4 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.3.[ADDRESS_1027635]  ...................................... 61 
8.4.2 Hepatitis and human immunodeficiency virus (HIV) screen ................ 62 
8.4.3 Laboratory evaluations  .......................................................................... 62 
8.4.4 Electrocardiogram (ECG) ..................................................................... 63 
8.4.5 Local tolerability (Injection site reactions)  ........................................... 63 
8.4.6 Pregnancy and assessments of fertility  ................................................. 63 
8.4.7 Tolerability of secukinumab  ................................................................. 63 
  64 
8.4.9 Other safety evaluations  ........................................................................ 64 
8.4.10 Appropriateness of safety measurements  .............................................. 64 
8.5 Additional assessments  .......................................................................................... 65 
  65 
8.5.2 Trial Feedback Questionnaires  .............................................................. 66 
  66 
8.5.4 HLA- B27............................................................................................... 66 
8.5.5 Pharmacokinetics  .................................................................................. 67 
  68 
8.5.7 Activity/Mobility improvement  ............................................................ [ADDRESS_1027636]- study treatment  .......................................................... 72 
10 Safety monitoring and reporting  ........................................................................................ 73 
10.1 Definition of adverse events and reporting requirements ...................................... 73 
10.1.1 Adverse events ...................................................................................... 73 
10.1.2 Serious adverse events (SAEs)  .............................................................. 75 
10.1.3 SAE reporting........................................................................................ 76 
10.1.4 Pregnancy reporting .............................................................................. 76 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 77 
10.2 Additional Safety Monitoring  ................................................................................ 77 

[COMPANY_001]  Confidential  Page 5 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
10.2.[ADDRESS_1027637] demographics and other baseline characteristics  ...................................... 81 
12.3 Treatments  ............................................................................................................. 82 
12.4 Analysis of the primary endpoint(s) ...................................................................... 82 
12.4.1 Definition of primary endpoint(s)  ......................................................... 82 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 83 
12.4.3 Handling of missing values/censoring/discontinuations ....................... 83 
12.4.4 Sensitivity and Supportive analyses ...................................................... 84 
12.5 Analysis of secondary endpoints  ........................................................................... 84 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s) .................................... 84 
12.5.2 Safety endpoints .................................................................................... 88 
12.5.3 Pharmacokinetics  .................................................................................. 89 
  90 
  90 
  90 
12.5.7 Patient Reported Outcomes (PROs)  ...................................................... 90 
  92 
12.7 Interim analyses  ..................................................................................................... 94 
12.8 Sample size calculation .......................................................................................... 95 
12.8.1 Primary endpoint(s)  ............................................................................... 95 
12.8.2 Secondary endpoint(s) ........................................................................... 95 
13 Ethical considerations and administrative procedures  ...................................................... 96 
13.1 Regulatory and ethical compliance ........................................................................ 96 
13.2 Responsibilities of the investigato r and IRB/IEC  .................................................. 96 
13.3 Publication of study protocol and results............................................................... 96 
13.4 Q uality Control and Quality Assurance  ................................................................. 97 
14 Protocol adherence  ............................................................................................................ 97 
14.1 Protocol amendments ............................................................................................. 97 
15 References  ......................................................................................................................... 98 
16 Appendices ...................................................................................................................... 101 

[COMPANY_001]  Confidential  Page 6 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
16.1 Appendix 1: Clinically notable laboratory values and vital signs ....................... 101 
16.2 Appendix 2: Modified [LOCATION_001] criteria ........................................................... 102 
16.3 Appendix 3: ASAS, BASFI  ............................................................ 102 
  104 
16.5 Appendix 5: Guidelines for administering the PRO questionnaires .................... 105 
16.6 Appendix 6: Liver event and laboratory trigger definitions and follow-up 
requirements ........................................................................................................ [ADDRESS_1027638] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 21 
Table 6 -1 Prohibited medication  ........................................................................... 38 
Table 8 -1 Assessment Schedule  ............................................................................ 47 
  58 
Table 8 -3 Assessments &  Specifications ............................................................... 60 
Table 8 -4 Specifications of Laboratory evaluations .............................................. 62 
  64 
Table 8 -6 PK sample log  ....................................................................................... 67 
  69 
  69 
Table 10-1 Guidance for capturin g the study treatment errors including 
misuse/abuse ......................................................................................... 77 
Table 12-1 Summary of power for binary secondary endpoints ............................. 95 
Table 12-2 Summary of power for continuous endpoints ....................................... 95 
Table 16-1 Safety Analyses: Expanded Limits and Notable Criteria  .................... [ADDRESS_1027639] of figures  
Figure 3-1 Study Design ......................................................................................... 28 
Figure 4-1 Median concentration profiles  ............................................................... 29 
Figure 12-1 Testing strategy  ..................................................................................... 88 
 

[COMPANY_001]  Confidential  Page 7 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
List of abbreviations  
AE adverse event  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ANCOVA  analysis of covariance  
AS Ankylosing spondylitis  
ASAS  Assessment of SpondyloArthritis International Society  
ASDAS  Ankylosing Spondylitis Disease Activity Score  
ASQoL  Ankylosing Spondylitis Quality of Life  
AST aspartate aminotransferase  
axSpA  Axial spondyloarthritis  
BASDAI  Bath Ankylosing Spondylitis Disease Activity Index   
BASFI  Bath Ankylosing Spondylitis Functional Index  
  
BDR  Bioanalytical Data Report  
BMI Body Mass Index  
BSL Baseline  
BUN  blood urea nitrogen  
Cavg Average concentration  
CFR Code of Federal Regulation  
CK creatine kinase  
Cmax Maximum concentration   
Cmin Minimum concentration  
CMO&PS  Chief Medical Office and Patient Safety  
CMV  Cytomegalovirus   
CO Country Organization  
CRA  Clinical Research Associate  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract Research Organization  
CRP  C-Reactive Protein  
cs-DMARD  conventional synthetic Disease Modifying Anti -rheumatic Drug  
CSR  Clinical Study Report  
CTC Common Toxicity Criteria  
Ctrough trough concentration  
CTT Clinical Trial Team  
DILI Drug -Induced Liver Injury   
DMARD  Disease Modifying Anti -rheumatic Drug  
  
EBV Epstein -Barr Virus   
EC Ethics committee  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  

[COMPANY_001]  Confidential  Page 8 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
eGFR  estimated glomerular filtration rate   
ELISA  Enzyme -linked immunosorbent assay  
EMA  European Medical Agency  
  
   
  
EU  European Union  
  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GCS  Global Clinical Supply  
GGT  gamma glutamyl transferase  
h hour 
HDL High Density Lipoprotein  
HIV human immunodeficiency virus  
HLA Human Leukocyte Antigen   
HRQoL  Health -related quality of life  
hsCRP  high sensitivity C -Reactive Protein  
HSV Herpes Simplex Virus   
i.v. intravenous  
IB Investigator's Brochure  
IBD inflammatory bowel disease   
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
  
INR International normalized ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
LDL Low Density Lipoprotein  
LFT Liver function test  
LiV Liquid in Vial  
LLN lower limit of normal  
LLOQ  Lower limit of quantification  
LOCF  Last Observation Carried Forward  
MAR  Missing at random  
  
  
MedDRA  Medical dictionary for regulatory activities  
mg milligram(s)  
ml milliliter(s)  
mL milliliter(s)  

[COMPANY_001]  Confidential  Page 9 
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
MMRM  Mixed effect Model for Repeated Measurements  
MRI Magnetic Resonance Imaging   
MTX  Methotrexate  
nr-axSpA  non-radiographic axial spondyloArthritis  
NSAID  Non-Steroidal Anti -Inflammatory Drug  
NY [LOCATION_001]  
PCS Physical Component Summary  
PD pharmacodynamic(s)  
PK pharmacokinetic(s)  
[COMPANY_003] Purified Protein Derivative   
PRN  as needed  
PRO  Patient Reported Outcomes  
PsA Psoriatic Arthritis  
PSQI  Pi[INVESTIGATOR_750605]  
q4w Every 4 weeks  
QMS  Quality Management System  
QoL Quality of Life   
RBC  Red blood cell(s)  
rem roentgen equivalent man  
s.c. subcutaneous  
SAE serious adverse event  
SCR  Screening  
SD standard deviation  
SF-36 Medical Outcome Short Form (36) Health Survey   
SF-[ADDRESS_1027640] operating procedure  
SpA Spondyloarthritis  
  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
Sv sievert (1 milliSv (mSv) = 100 millirem (mrem))  
t.i.d three times a day  
TBIL/TBL  total bilirubin  
TNF-IR  TNFα Inhibitor Incomplete Responder  
TNF/TNFα  Tumor Necrosis Factor   
ts-DMARD  targeted synthetic Disease Modifying Anti -rheumatic Drug  
ULN upper limit of normal  
US [LOCATION_002]  

[COMPANY_001]  Confidential  Page 10  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
VAS Visual Analog Scale   
vs. versus  
WBC  white blood cell(s)  
WHO  World Health Organization  
  

[COMPANY_001]  Confidential  Page 11  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_536796]  A study drug used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug.  
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Enrollment  Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)  
Investigational 
drug The study drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synonymous with “investigational new drug” or “test substance”  
Investigational 
treatment  All investigational drug(s) whose properties are being tested in the study as 
well as their associated treatment controls. This includes any placebos, any 
active controls, as well as approved drugs used outside of their 
indication/approved dosage or tested in a fixed combination. Investigational 
treatment generally does not include other treatments administered as 
concomitant background therapy required or allowed by [CONTACT_331985]/dosage.  
Medication 
number  A unique identifier on the label of each study drug package in studies that 
dispense study drug using an IRT system.  
Medication pack 
number  A unique identifier on the label of each drug package in studies that dispense 
study treatment using an IRT system  
Patient  An individual with the condition of interest  
Period  A minor subdivision of the study timeline; divides phases into smaller functional 
segments such as screening, baseline, titration, washout, etc.  
Premature 
subject 
withdrawal  Point/time when the subject exits from the study prior to the planned completion of all study drug administration and assessments; at this time all study drug 
admi nistration is discontinued and no further assessments are planned.  
Randomization 
number  A unique identifier assigned to each randomized subject, corresponding to a 
specific treatment arm assignment  
Screen Failure  A subject who is screened but is not trea ted or randomized  
Study completion Point/time at which the subject came in for a final evaluation visit or when study 
drug was discontinued whichever is later.  
Study drug 
discontinuation  Point/time when subject permanently stops taking study drug for any reason; 
may or may not also be the point/time of premature subject withdrawal.  
Study 
drug/treatment  Any drug (or combination of drugs) administered to the subject as part of the 
required study procedures; includes investigational drug, active drug run-ins or 
background therapy.  
Study treatment  Any drug administered to the study participants as part of the required study procedures; includes investigational drug (s), control(s) or non -investigational 
medicinal product(s)  
Study treatment 
discontinuation  When the subject permanently stops taking study treatment prior to the defined 
study treatment completion date  
Subject  An individual who has consented to participate in this study. The term Subject 
may be used to describe either a healthy volunteer or a patient.  
[COMPANY_001]  Confidential  Page 12  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Subject number  A unique number assigned to each subject upon signing the informed consent. 
This number is the definitive, unique identifier for the subject and should be used to identify the subject throughout the study for all data collected, sample 
labels, etc.  
Variable  Information used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints.  
Withdrawal of 
consent (WoC)  Withdrawal of consent from the study is defined as when a subject does not w
ant to participate in the study any longer  and does not want any further visits 
or assessments  and does not want any further study related contact  [CONTACT_750622] 13  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Protocol summary  
Protocol 
number  CAIN457P12301  
Full Title  A randomized, double- blind, placebo- controlled, parallel group, phase III 
multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with 
placebo and to assess safety and tolerability up to 52 weeks in subjects with active 
Ankylosing Spondylitis or non -radiographic axial SpondyloArthritis  
Brief title  Study to demonstrate the efficacy, safety and tolerability of an intravenous (i.v.) 
regimen of secukinumab compared to placebo in su bjects with active axSpA  
Sponsor and 
Clinical Phase  [COMPANY_001]  
Phase III  
Investigation 
type Biological  
Study type  Interventional  
Purpose and 
rationale  The purpose of this global study is to demonstrate the efficacy, safety, and 
tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in subjects with active axSpA at Week [ADDRESS_1027641] 
and/or anti Tumor Necrosis Factor  (TNF) therapy. In addition, to further support 
efficacy and safety of an i.v. regimen, data will be collected for up to 52 weeks of 
treatment. Efficacy and safety data may be used to support the registration of i.v. 
secukinumab in the US and other countries for treatment of subjects with active 
axSpA.  
Primary 
Objective(s)  To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to placebo in subjects with active axspA (AS and nr- axSpA) based on the proportion 
of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International 
Society criteria) response . 
Secondary Objectives  1. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to placebo based on the proportion of subjects achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) -C-Reactive Protein (CRP)  major 
improvement   
2. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI)   
3. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the proportion of subjects meeting the ASAS 5/6 
response criteria  
4. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on Bath Ankylosing Spondylitis Functional Index  (BASFI)  
5. To evaluate the efficacy of i.v. secukinumab compared to placebo after 16 
weeks of treatment by [CONTACT_750623] -36 Physical Component 
Summary (SF -36 PCS)  
6. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the change from baseline in Ankylosing Spondylitis 
Quality of Life (ASQoL) scores  
7. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the change from baseline in high sensitivity C- Reactive 
Protein (hsCRP)   
[COMPANY_001]  Confidential  Page 14  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the proportion of subjects achieving an ASAS20 response  
9. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the proportion of subjects  achieving Ankylosing 
Spondylitis Disease Activity Score (ASDAS) -C-Reactive Protein (CRP) inactive 
disease  
10. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the proportion of subjects achieving ASAS partial 
remission  
11. To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior 
to placebo based on the change from baseline in Pi[INVESTIGATOR_6041] (PSQI)  
12. Overall safety and tolerability of i.v. secukinumab compared to placebo as assessed by [CONTACT_750624], vital signs, laboratory assessments and adverse 
event monitoring  
Study design  This multicenter study uses a randomized, double- blind, placebo- controlled, 
parallel -group design to study the efficacy, safety, and tolerability of treatment with 
intravenous secukinumab (initial dose of 6 mg/kg followed thereafter with 3 mg/kg 
administered every four weeks starting at Week 4) in subjects  with active axSpA.  
Population  The study population will consist of male and female subjects (≥18 years old at the 
time of consent) with active axSpA (radiographic AS or non- radiographic axSpA). 
The diagnosis of axSpA must fulfill the ASAS criteria of inflammatory back pain for at least [ADDRESS_1027642] fulfill the Modified [LOCATION_001] criteria for ankylosing spondylitis with prior 
documented radiological evidence (x- ray or a radiologists report).  
Subjects with nr -axSpA  (no definitive radiographic evidence of changes in the 
sacro iliac joints that would meet the modified [LOCATION_001] criteria for AS) must fulfill 
the following ASAS classification criteria for axSpA:  
a. Sacroiliitis on MRI with ≥ 1 SpA feature OR HLA -B-27 is positive with ≥2 SpA 
features AND  
b. Objective signs of inflammation at screening, evident by [CONTACT_750625] / OR hsCRP > ULN (as defined by [CONTACT_6626])  
In addition, all subjects must have evidence of active axSpA as measured by [CONTACT_750626]:  
• total BASDAI ≥4 cm on a scale of 0- 10 cm  
• spi[INVESTIGATOR_90150] #2 ≥4 cm (0 -10 cm)  
• total back pain as measured by [CONTACT_110438] (VAS) ≥40 mm (0-100 mm)  
Included subjects must have evidence of active disease despi[INVESTIGATOR_250306], conven tional DMARD and/or anti -TNF therapy.  
This is a global interventional study and it expected that approximately 500 subjects 
are randomized (400 with active AS and 100 with nr -axSpA) to evaluate the efficacy 
and safety of intravenous secukinumab in this sub ject population.  
Key Inclusion 
criteria  1. Subject must be able to understand and communicate with the investigator, 
comply with the requirements of the study. and must give written, signed and dated 
informed consent before any study assessment is perform ed 
2. Male and non- pregnant, non- lactating female patients ≥ 18 years of age  
3. Diagnosis of axSpA according to ASAS criteria  
[COMPANY_001]  Confidential  Page 15  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
a. Inflammatory back pain for at least 6 months  
b. Onset before 45 years of age  
4. For subjects with AS: Diagnosis of moderate to severe AS with prior documented 
radiologic evidence (x -ray or radiologist’s report) fulfilling the Modified [LOCATION_001] 
criteria for AS  
5. For subjects with nr- axSpA:   
X-ray of SIJ negative (centrally read) for AS by [CONTACT_750627]  
a. Sacroiliitis o n MRI (centrally read) with ≥ 1 SpA feature OR HLA -B-27 positive 
with ≥2 SpA features AND  
b. Objective signs of inflammation at screening, evident by [CONTACT_750628] (centrally read) AND / OR hsCRP > ULN (as defined by [CONTACT_27681]) 
6. Active axial SpA assessed by [CONTACT_750629] ≥4 cm (0 -10 cm) at Baseline  
7. Spi[INVESTIGATOR_90150] #2 ≥ 4 cm (0 -10 cm) at Baseline 
8. Total back pain as measured by [CONTACT_8298] ≥ 40 mm (0 -100 mm) at Baseline  
9. Subjects should have had inadequate response or failure to respond to at least 
2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum 
of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or contr aindications  
10. Subjects who are regularly taking NSAIDs (including COX -1 or COX -2 
inhibitors) as part of their AS or nr- axSpA therapy are required to be on a stable 
dose for at least [ADDRESS_1027643] been inadequate responders to a TNF inhibitor (not more than one) will be allowed to enter into the study (not more than 20% per group). They must have experienced an inadequate response to previous 
or current treatment at an approved dose for at least [ADDRESS_1027644] one administration of an anti-TNF 
agent.  These subjects will undergo an appropriate wash- out period prior to 
randomization, if required  
a. 4 weeks for Enbrel® (etanercept) – with a terminal half -life of 102 ±  
30 hours  
b. 8 weeks for Remicade® (infliximab) – with a terminal half -life of 8.0 -9.5 days  
c. 10 weeks for Humira® (adalimumab) – with a terminal half -life of 10- 20 days  
(average 2 weeks)  
d. 10 weeks for Simponi® (golimumab) – with a terminal half -life of 11- 14 days  
e. 10 weeks for Cimzia® (certolizumab) – with a terminal half -life of 14 days  
12.Subjects taking methotrexate (MTX) (≤ 25 mg/week ) or sulfasalazine (≤ 3 g/day) 
are allowed to continue their medication and must have taken it for at least [ADDRESS_1027645] be be discontinued 8 weeks prior to randomization, unless 
a cholestyramine washout has been performed  
[COMPANY_001]  Confidential  Page 16  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
14.Subjects taking systemic corticosteroids must be on a stable dose of ≤10 
mg/day prednisone or equivalent for at least [ADDRESS_1027646] x- ray or MRI with evidence of ongoing infectious or malignant process 
obtained within 3 months of screening and evaluated by a qualified physician  
3. Subjects taking moderate and high potency opi[INVESTIGATOR_2467] (e.g. methadone, hydromorphone, morphine) 
4. Presence of significant medical problems which at investigator’s discretion, will 
prevent the subject  from participating in the study, including but not limited to the 
following: Subjects with severely reduced kidney function (estimated glomerular filtration rate (eGFR) <29 ml/min/1.73m
2), history of renal trauma, 
glomerulonephritis, or patients with one kidney only, or a serum creatinine level 
exceeding 1.5 mg/dl (132.6 μmol/L)  
5. Any therapy by [CONTACT_90169] -articular injections (e.g. corticosteroid) within 4 weeks 
before r andomization  
6. Underlying conditions (including, but not limited to metabolic, hematologic, renal, 
hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opi[INVESTIGATOR_37195]
y immunocompromises the 
subject and/or places the subject at unacceptable risk for receiving an 
immunomodulatory therapy  
7. Any medical or psychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would 
preclude the participant from adhering to the protocol or completing the study per 
protocol  
8. Active systemic infections during the last two weeks (exception: common cold) 
prior to randomization or any infection that reoccurs on a regular basis  
9. History of ongoing, chronic or recurrent infectious diseas e or evidence of 
tuberculosis infection as defined by [CONTACT_5640] a positive purified protein derivative 
([COMPANY_003]) skin test (the size of induration will be measured after 48-72 hours, and a 
positive result is defined as an induration of ≥ 5 mm or according to loca l 
practice/guidelines) or a positive QuantiFERON TB -Gold test as indicated in the 
assessment schedule in Table 8-[ADDRESS_1027647] may participate in 
the study if further work up (according to local practice/guidelines) establishes 
conclusively that the subject has no evidence of active tuberculosis. If presence of 
latent tuberculosis is established, then treatment according to local country 
guidelines must have been initiated  
10. Past medical history of infection with HIV or hepatitis B prior to randomization 
or active infection or on treatment for Hepatitis C at randomization  
11. History of lymphoproliferative disease or any known malignancy, or history of 
malignancy of any organ system treated or untreated within the past 5 years, 
regardless of whether there is evidence of local recurrence or metastases (except 
for skin Bowen’s disease, or basal cell carcinoma or actinic keratoses that have 
been treated with no evidence of recurr ence in the past 12 weeks; carcinoma in 
situ of the cervix or non -invasive malignant colon polyps that have been removed)  
12. Inability or unwillingness to undergo repeated venipuncture (e.g., because of 
poor tolerability or lack of access to veins)  
[COMPANY_001]  Confidential  Page 17  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
13. Pr egnant or nursing (lactating) women, where pregnancy is defined as the state 
of a female after conception and until the termination of gestation, confirmed by a 
positive hCG laboratory test  
14. Screening total WBC count <3,000/μl, or platelets <100,000/μl or 
neutrophils  <1,500/μl or hemoglobin <8.5 g/dl (85 g/L)  
15. History of clinically significant liver disease or liver injury indicated by [CONTACT_750630], such as SGOT (AST), SGPT (ALT), alkaline phosphatase and 
serum bilirubin. The investigator should be guided by [CONTACT_4868]:  
· Any single parameter may not exceed 2 x the upper limit of normal (ULN). A single 
parameter elevated up to and including [ADDRESS_1027648] prior to randomization, to rule -out 
laboratory error.  
· If the total bilirubin concentration is increased above [ADDRESS_1027649] reacting bilirubin. In any case, serum 
bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L)  
16. Significant medical problems or diseases, including but not limited to the 
following:  
uncontrolled hypertension (≥160/95 mmHg), congestive heart failure ([LOCATION_001] Heart Association status of class III or IV), un controlled diabetes, or very poor 
functional status precluding ability to perform self -care 
17. Women of child- bearing potential, defined as all women physiologically capable 
of becoming pregnant, unless they are using effective methods of contraception 
during the entire study or longer if required by [CONTACT_750631] (e.g., 20 weeks in EU)  
18. Active ongoing inflammatory diseases other than axSpA that might confound the evaluation of the benefits of secukinumab therapy, including inflammatory 
bowel disease or uveitis  
19. Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the subject unsuitable for the trial  
20. Use of other investigational drugs at the time of enrollment, or within [ADDRESS_1027650] 
has returned to baseline, whichever is longer; or longer if required by [CONTACT_13125]  
21. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL -17 or the IL- 17 receptor  
22. Previous treatment with any cell -depleting therapi[INVESTIGATOR_750606]-CD20 or investigational agents (e.g., CAMPATH, anti -CD4, anti -CD5, anti -
CD3, anti -CD19)  
Study treatment  At baseline, subjects with active AS and nr- axSpA will be randomized to one of the 
two treatment groups:  
Group 1: approximately 200 AS subjects and 50 nr -axSpA subjects;  These subjects 
will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by [CONTACT_750632] 
3 mg/kg i.v. every four weeks 
starting at Week 4 through Week 48 (exposure through week 52).  
Group 2: approximately 200 AS subjects and 50 nr -axSpA subjects;  These subjects 
will receive  i.v. placebo  at ran domization (BSL visit), Weeks 4, 8, and 12 , followed 
[COMPANY_001]  Confidential  Page 18  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
by [CONTACT_750632] 3 mg/kg i.v. at Week 16 and every four weeks 
through Week 48  (exposure through week 52).  
Efficacy 
assessments  • Assessment of SpondyloArthritis International Society (ASAS) response 
criteria; ASAS40, ASAS20, ASAS 5/6 and ASAS partial  remission  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
• Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50)  
• Bath Ankylosing Spondylitis Functional Index (BASFI)  
• Patient’s global assessment of disease activity (VAS)  
• Patient’s assessment of back pain intensity (VAS)  
  
• Medical Outcome Short Form Health Survey (SF -36) Version 2 (Acute Form)  
• Ankylosing Spondylitis Quality of Life (ASQoL)  
• High sensitivity C- Reactive Protein (hsCRP)  
  
  
 
• Ankylosing Spondylitis Disease Activity Score (ASDAS) -C-Reactive Protein 
(CRP) and ASDAS response categories  
  
  
• Sleep improvement (  sleep PROs)  
Key safety 
assessments  • Physical examination  
• Vital signs  
• Height and weight  
• QuantiFERON TB -Gold test or [COMPANY_003] skin test  
• Hepatitis and human immunodeficiency virus (HIV) screen  
• Laboratory evaluations (Hematology, clinical chemistry, lipid panel, 
cardiovascular Panel, urinalysis and pregnancy test)  
• Evaluation of AE/ SAE’s  
• Local tolerability (Injection site reactions)  
• Pregnancy and assessment of fertility  
• Tolerability of secukinumab 
  
Other assessments  • Quality of Life questionnaires/ Patient reported outcomes (PROs)  
• Trial Feedback Questionnaires  
  
• HLA-B27 
• Pharmacokinetics  
  
• Activity/Mobility improvement  
• Sacroiliac Joint X -ray 
• Sacroiliac Joint MRI  
Data analysis  The primary endpoint in the study is the proportion of subjects who achieve an 
ASAS40 response at Week 16. The statistical hypothesis for ASAS40 being tested 

[COMPANY_001]  Confidential  Page 19  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
is that there is no difference in the proportion of subjects fulfilling the ASAS40 
criteria at Week 16 in the secukinumab i.v. regimen versus placebo.  
Let p 0 denote the proportion of ASAS40 responders at Week 16 for placebo 
regimen and p 1 denote the proportion of ASAS40 responders at Week 16 for 
secukinumab i.v. regimen.  
In statistical terms, H 1: p1= p 0, HA1: p1≠ p 0, i.e.,  
H1: secukinumab i.v. regimen is not different to placebo regimen with respect to 
ASAS40 response at Week 16 
The primary endpoint of ASAS40 at Week 16 in the FAS will be evaluated using a 
logistic regression with treatment and randomization stratum (disease condition) as 
factors and weight as a covariate. Difference in marginal response proportions with 
p-value and respective 95% confidence interval will be estimated from the logistic 
regression model for the comparison of secukinumab i.v. regimen versus placebo.  
The secondary endpoints include ASDAS -CRP major improvement, BASDAI, 
ASAS 5/6, BASFI, SF -36 PCS, ASQoL, hsCRP, ASAS20, ASDAS-CRP inactive 
disease, ASAS partial remission and PSQI at Week 16.  
The binary secondary endpoints (e.g.,  ASAS 5/6, etc.) will be evaluated via a 
logistic regression with treatment and randomization stratum (disease condition) as factors and weight as a covariate.  
The change from baseline in continuous secondary endpoints (e.g., BASDAI, etc.) will be evaluated using MMRM with treatment group, stratification factor (disease condition) and analysis visit as categorical factors, baseline measure and weight 
as continuous covariates, and treatment by [CONTACT_750633]. An unstructured covariance structure will be assumed for the model.  
Safety analyses will include summaries of AEs, laboratory measurements, and vital 
signs.  
Key words  Active axSpA, Axial spondyloarthritis, non -radiographic -axSpA, nr -axSpA, 
anky losing spondylitis, AS, inflammatory back pain, sacroiliitis, intravenous 
secukinumab  
[COMPANY_001]  Confidential  Page 20  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
1 Introduction  
1.1 Background 
Axial spondyloarthritis (axSpA) is a type of spondyloarthritis mainly affecting the axial 
skeleton, characterized by [CONTACT_15209][INVESTIGATOR_750607]. AxSpA is among 
the most common chronic inflammatory joint disorders, with recent estimates of prevalence in Caucasian populations in the range of 1–2% ( Baraliakos and Braun  2011). Patients with chronic 
back pain (onset before 45 years of age) are classified as having axSpA if they fulfill either the clinical arm or the imaging arm of the Assessment of SpondyloArthritis International Society (ASAS)  classification criteria ( Rudwaleit  et al 2009).  
Based on the presence or absence of sacroiliitis on conventional X -ray radiographs, axSpA 
patients are further classified into two conditions: non -radiographic- axSpA (nr -axSpA) and 
ankylosing spondylitis (AS). Patients with evidence of sacroiliitis on X -ray fulfilling the 1984 
modified [LOCATION_001] diagnostic criteria ( van der Linden et  al 1984) are classified as having AS, 
whereas patients who do not show sacroiliitis on X -ray, but may show evidence of sacroiliitis 
on MRI, are classified as having nr -axSpA.  
AS is characterized mainly by [CONTACT_750634] (SI) joints, but peripheral joints, entheses and extra -articular organs may also be affected. A significant 
proportion of AS patients may present with associated extra -articular manifestations such as 
uveitis, psoriasis, inflammatory bowel disease (IBD), or cardiovascular and pulmonary abnormalities. Generalized osteoporosis, as well as regional osteopenia are common in AS patients and predispose them to non -traumatic fractures, despi[INVESTIGATOR_040] a predominantly younger age 
and male gender distribution. The presence of the Human Leukocyte Antigen (HLA) -B27 is 
strongly associated with AS; 90–95% of patients with AS who have European ancestry carry this marker. AS affects up to 1.1% of the population, is associated with significant morbidity and disability, and thus constitutes a major socioeconomic burden. 
Studies and registry data have shown that nr -axSpA patients have similar levels of disease 
activity, pain, and health- related quality of life impairment as observed in AS patients 
(Wallis et al 2013). Disease parameters and response rates to treatment with tumor necrosis 
factor (TNF) antagonists are similar in patients with AS and nr- axSpA, supporting the concept 
that axSpA is  a disease with distinct stages ( Song et  al 2013). Furthermore, with a longer 
duration of symptoms, most patients who start with nr -axSpA ultimately develop radiographic 
evidence consistent with AS. In an investigation of 329 patients with axSpA, evidence of 
radiographic sacroiliitis was present in 40 -86% of patients, in accordance with the duration of 
symptoms (<10 to  > 20 years) ( Said-Nahal  et al 2000 ), with many nr- axSpA patients 
progressing to AS over time. Nonetheless, it is estimated that 10 -15% of nr -axSpA patients do 
not develop radiographic sacroiliitis ( Sieper  and van der H eijde  2013). Thus, nr -axSpA may 
represent an early stage of AS, but may also be a form of the disease which causes much pain without leading to structural changes of the axial skeleton (Baraliakos  and Braun  2015). In 
short, patients recognized as having axSpA, either with AS or nr -axSpA, present with similar 
clinical characteristics, the same burden of disease, and the same response to anti -inflammatory  
medication. A study evaluating the efficacy and safety of secukinumab 150 mg s.c. q4w vs. placebo (CAIN475H2315) in patients with nr-axSpA is currently ongoing. 
[COMPANY_001]  Confidential  Page 21  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
First-line medication of mild AS consists of non -steroidal anti -inflammatory drugs (NSAIDs). 
Treatment of NSAID -refractory AS is hampered by [CONTACT_750635] -rheumatic drugs (DMARDs), including methotrexate 
(MTX). As an  exception, peripheral arthritis associated with AS may respond to sulfasalazine 
and methotrexate. TNF blocking agents were successfully added to the armamentarium to treat 
AS ( Braun  et al 2002 ) and subsequently demonstrated prolonged efficacy up to eight year s of 
follow -up (Baraliakos et  al 2011 ). However, upon discontinuation of TNF blockers the disease 
relapses quickly ( Baraliakos et  al 2005), indicating that the inflammatory process may have 
only been inhibited but not completely abolished. 
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the 
proinflammatory cytokine interleukin- 17A (I L-17A). Secukinumab targets IL -17A, inhibiting 
its interaction with the IL -17 receptor expressed on various cell types including keratinocytes 
and synoviocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and medi ators of tissue damage and reduces IL -17A- mediated contributions to 
autoimmune and inflammatory diseases, including psoriasis, psoriatic arthritis (PsA) and AS.  
To date, s.c. secukinumab is  approved in over 90 countries for the clinical management of PsA 
and AS. 
1.2 Purpose 
The purpose of this global study is to demonstrate the  efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in subjects with active axSpA, including AS and nr -axSpA at Week [ADDRESS_1027651] and/or anti TNF therapy. In addition, to further support efficacy and safety of an i.v. regimen, data will be collected for up to 52 weeks of treatment. Efficacy and safety data may be used to support the registration of i.v. secukinumab in the US and other countries for treatment of subjects with active axSpA.  
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to placebo in subjects with active axSpA (AS and nr-axSpA) based on the proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International Society criteria) response.  • ASAS40 response at Week 16, defined as improvement of ≥ 40% and an absolute improvement from baseline of ≥20 units (range 0–100) in ≥ 3 of the following  4 domains: 
back pain [10 cm visual analogue scale (VAS)], patient global assessment of disease activity (10 cm VAS), physical function (BASFI; range 0–100) 
and inflammation (mean score 
[COMPANY_001]  Confidential  Page 22  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Objective(s)  Endpoint(s)  
of items 5 and 6 of the 
BASDAI; both 10 cm VAS) 
without any worsening in the 
remaining domain.  
Secondary objective(s)  Endpoint(s) for secondary 
objective(s)  
• To demonstrate that the efficacy of i.v. secukinumab at Week [ADDRESS_1027652] ivity Score 
(ASDAS) -C-Reactive Protein (CRP)  major 
improvement   • ASDAS -CRP major 
improvement defined as a change (decrease) in the score of at least 2.0 units   
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based on the change from baseline in total Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)   • Change from baseline in total BASDAI  
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on the proportion of subjects meeting the 
ASAS 5/6 response criteria   • Subjects achieving ASAS 5/6 response defined as: improvement of ≥20% in at 
least five of six domains  
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on Bath Ankylosing Spondylitis Functional 
Index  (BASFI)  • Change from baseline of BASFI  
• To evaluate the efficacy of i.v. secukinumab compared to placebo after 16 weeks of treatment by [CONTACT_750623]-36 Physical Component 
Summary (SF -36 PCS)  • Absolute & percent change 
from baseline in SF -36 PCS  
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on the change from baseline in Ankylosing 
Spondylitis Quality of Life (ASQoL) scores  • Absolute & percent change from base line in ASQoL  
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on the change from baseline in high 
sensitivity C -Reactive Protein (hsCRP)   • Change from baseline in hsCRP  
• To demonstrate that the efficacy of i.v. 
secukinumab at Week 16 is superior to  placebo 
based on the proportion of subjects achieving an ASAS20 response • The ASAS Response Criteria (ASAS20) is defined as an improvement of ≥20% and ≥[ADDRESS_1027653] three of the four main domains 
and no worsening of ≥20% and 
[COMPANY_001]  Confidential  Page 23  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Objective(s)  Endpoint(s)  
≥1 unit on a scale of 10 in the 
remaining domain.  
• To demonstrate that the efficacy of i.v. 
secukinumab at Week 16 is superior to  placebo 
based on the proportion of subjects achieving Ankylosing Spondylitis Disease Activit y Score 
(ASDAS) -C-Reactive Protein (CRP)  inactive 
disease   • ASDAS -CRP inactive disease 
as defined by  [CONTACT_750636] -CRP 
score below 1.3 
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on the proportion of subjects achieving 
ASAS partial remission  • ASAS partial remission criteria are defined as a value not above 2 units in each of the four main ASAS domains on a 
scale of 0 -10 
• To demonstrate that the efficacy of i.v. secukinumab at Week 16 is superior to  placebo 
based  on the change from baseline in Pi[INVESTIGATOR_22336] (PSQI)   • Change from baseline in PSQI 
• Overall safety and tolerability of i.v. secukinumab compared to placebo as assessed by [CONTACT_750624], vital signs, laboratory assessments and 
adverse event monitoring  • Physical exams, vital signs, laboratory assessments, and adverse event monitoring 

[COMPANY_001]  Confidential  Page 24  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Objective(s)  Endpoint(s)  

[COMPANY_001]  Confidential  Page 25  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 

[COMPANY_001]  Confidential  Page 26  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Objective(s)  Endpoint(s)  
3 Study design  
This multicenter study uses a randomized, double -blind, placebo- controlled, parallel -
group design  to study the efficacy, safety, and tolerability of treatment with intravenous 
secukinumab (initial dose of 6 mg/kg followed thereafter with 3 mg/kg administered every four 
weeks starting at Week 4)  in subjects  with active axSpA. The  study population consists 
of approximately [ADDRESS_1027654] and / or TNF inhibitor 
therapy, or intolerance to these therapi[INVESTIGATOR_014]. A screening (SCR) period of up to 10 weeks will be used to assess eligibility, followed by [CONTACT_97222] 52 weeks of study treatment.   
At baseline, subjects with active AS and nr -axSpA will be randomized to one of the two 
treatment groups:  
• Group 1: approximately 200 AS subjects and approximately 50 nr-axSpA subjects; These subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BS L) visit), 
followed by [CONTACT_750632] 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52). 
• Group 2: approximately 200 AS subjects and approximately 50 nr- axSpA subjects; These 
subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , 

[COMPANY_001]  Confidential  Page 27  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
followed by [CONTACT_750632] 3 mg/kg i.v. at Week 16 and every four 
weeks through Week 48 (exposure through Week 52). 
This study will consist of 4 periods totaling 70 weeks: the screening period (up to 10 weeks), the treatment period 1 (total duration of 16 weeks) and the treatment period 2 (total duration of 36 weeks) followed by [CONTACT_750637] 8 weeks after the end of treatment visit (i.e., Week 52). 
The subj ects will be stratified at randomization according to disease condition (i.e., AS or nr-
axSpA). No more than 20% TNF Inhibitor Incomplete Responders (TNF -IR) subjects will be 
enrolled in the study. Starting at Week 16, all subjects will switch to open-labe l intravenous 
secukinumab, including all placebo subjects. No subject will be on placebo treatment after Week 16, because axSpA is considered a chronic 
disease with no ‘true’ and lasting placebo response. However, all subjects and investigators/site staff will remain blinded to the original randomized treatment group assignment (secukinumab 
treatment vs placebo). Study treatment will continue up to Week 52. An end of treatment visit (i.e., Week 52) is to be done [ADDRESS_1027655] 
treatment follow -up visit (i.e., Week 60) is to be done 8 weeks after the end of treatment visit 
for all subjects (regardless of whether they complete the entire study as planned or discontinue prematurely). All i.v. infusions will be perfo rmed at the study site and site personnel will 
administer the infusions to subjects.  
Rescue medication is not allowed until Week 16. However, subjects who are deemed by [CONTACT_750638]. The study will have a primary endpoint analysis at Week 16. Therefore, 
the primary analysis will be performed with Week -[ADDRESS_1027656] has completed 
the Treatment Period 1.  
[COMPANY_001]  Confidential  Page 28  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Figure 3-1 Study Design 
 
4 Rationale  
4.1 Rationale for study design  
The double -blind, randomized, parallel -group, placebo- controlled design used in this study is 
aligned with Phase III trials of other biologics and is in accordance with EMA (European 
Medical Agency) guidelines ( EMA  2017) and available precedent. The treatment duration of 
the placebo group has been kept short and the group will be re -assigned to active treatment once 
the Week [ADDRESS_1027657] of the route of 
administration on the efficacy response.  
4.1.1 Rationale for choice of background therapy 
Clinical management of axSpA by [CONTACT_750639], and if insufficient response, biologic agents (i.e., TNF -inhibitor 
therapy or anti-IL17 agents). 
[COMPANY_001]  Confidential  Page 29  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
This study intends to enroll patients with active disease despi[INVESTIGATOR_750608], 
conventional DMARDs and/or TNF inhibitor therapy or intolerance to these therapi[INVESTIGATOR_014]. A background of NSAID therapy and/or concomitant therapy with methotrexate (≤25 mg/week) or sulfasalazine (≤ 3 g/day) will be acceptable, if dose and route of administration have been stable for at least two weeks with NSAIDs and/or four weeks with M TX or sulfasalazine, prior 
to the randomization visit. Inclusion of patients with active axSpA who are TNF -IR (up to 20% 
in each group) in the study also makes the background patient population more representative of the real world clinical scenario.  
4.2 Ratio nale for dose/regimen and duration of treatment  
  
 H 
ence, the proposed i.v. 
regimen is expected to deliver an exposure within the  approved s.c. doses of secukinumab. 
Considering the large amount of clinical data collected so far and understanding of the PK profile for secukinumab in AS, it is expected that the clinical response with the proposed i.v. regimen will be similar to that observed with current approved s.c. regimens. 
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs  
A placebo arm up to the primary endpoint at Week 16 is included in this study. Due to the nature 
of the disease and the outcome measures used (ASAS criteria), a placebo arm is necessary to reliably evaluate the efficacy and safety of the active drug. The continuation of the placebo 

[COMPANY_001]  Confidential  Page 30  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
group up to the primary endpoint assessment at Week 16 can be supported from an ethical 
standpoint, as subjects can continue on a range of concomitant treatments. 
The parallel -group placebo controlled design used in this study is aligned with Phase III trials 
of other biologics in this disease area including registration studies of s.c. secukinumab in 
axSpA and is also in accordance with EMA guidelines ( EMA  2017).  The treatment duration of 
the placebo group is relatively short and the placebo group will be re -assigned to active 
treatment at Week 16. The regular assessment of disease activity ensures that subjects who are experiencing worsening of disease in any of the treatment groups can exit the study at any time upon their own accord or based on the advice of the investigator. 
4.4 Purpose and timing of interim analyses/design adaptations  
The primary endpoint analysis (Week -16 analysis) will be performed after all subjects complete 
the Week -16 visit in order to support regulatory f ilings.  
Additional analyses may be performed to support health authority interactions, as necessary. 
The investigators, site personnel, subjects and monitors will remain blinded to the original 
treatment assignment groups until Week -60 analysis has been completed. 
4.5 Risks and benefits  
Secukinumab has demonstrated either preliminary or confirmed efficacy in several inflammatory diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. The safety profile of secukinumab is primarily ba sed on the aggregate safety data from 10 large 
completed phase II/III psoriasis trials. The evaluation of safety data from completed phase II/III AS trials did not show additional safety concerns.  
Secukinumab was generally safe and well -tolerated. The most  frequently reported adverse 
events are infections, especially upper respi[INVESTIGATOR_750609].  
There was an increase in mucosal or cutaneous candidiasis with secukinumab compared to placebo, but the cases were mostly mild or moderate in severity, non- serious, and responsive to 
standard treatment.  
There was a small increase in mild neutropenia cases with secukinumab compared to placebo.  
Common Toxicity Criteria (CTC) AE grade 3 neutropenia (<1.0-0.5x10
9/L) was uncommonly 
observe d with secukinumab, most were transient and reversible without a temporal relationship 
to serious infections.  
Hypersensitivity reactions including urticarial and a rare event of anaphylactic reaction to secukinumab were also observed in clinical studies.  
Taking into account the individual risks as outlined above, the expected risk profile of the i.v. 
regimen of secukinumab from a mechanism of action perspective is anticipated to be similar to that seen with th e approved s.c. secukinumab regimens. The risk t o subjects in this trial will be 
minimized by [CONTACT_178438], close clinical monitoring and extensive guidance to the investigators, provided in the current version of the Investigator’s Brochure (IB).  
[COMPANY_001]  Confidential  Page 31  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Women of child bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and must agree that in order to participate in the study they must adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the subject will not reliably comply, they should not be entered or continue in the study. 
From the standpoint of the overall risk- benefit assessment, the current trial with secukinumab 
is justified.  
[ADDRESS_1027658] of male and female subjects (≥18 years old at the time of 
consent) with active axSpA (AS or nr -axSpA). The diagnosis of axSpA must fulfill the ASAS 
criteria of inflammatory back pain for at least [ADDRESS_1027659] fulfill the Modified [LOCATION_001] criteria for AS (see Section  16.2 ) with prior documented radiological evidence (x- ray or a radiologists report).  
Subjects with nr -axSpA (no definitive radiographic evidence of changes in the sacroiliac joints 
that would meet the modified [LOCATION_001] criteria for AS) must fulfill the following ASAS classification criteria for axSpA:  
a. Sacroiliitis on MR I (centrally read) with ≥ 1 SpA feature OR HLA -B27 is positive with 
≥2 SpA features AND  
b. Objective signs of inflammation at screening, evident by [CONTACT_750640] (centrally read) AND / OR hsCRP > ULN (as defined by [CONTACT_6626]) 
In addition, all subjects must have evidence of active axSpA as measured by [CONTACT_750641]:  
• total BASDAI ≥4 cm on a scale of 0-10 cm 
• spi[INVESTIGATOR_90150] #2 ≥4 cm (0 -10 cm) 
• total back pain as measured by [CONTACT_110438] (VAS) ≥40 mm (0 -100 mm) 
Included subjects must have evidence of active disease despi[INVESTIGATOR_250306], 
conventional DMARD and/or anti-TNF therapy. 
This is a global interventional study and it is expected that approximately 500 subje cts are 
randomized  (approximately 400 subjects with active AS and approximately 100 subjects with 
nr-axSpA) to evaluate the efficacy and safety of i.v. secukinumab in this subject population. 
A screening failure rate of 25% and post -randomization drop -out rate of 10% prior to the time 
of the primary endpoint assessments (Week 16) are anticipated. Enrollment will stop as soon as 
the target number of randomized subjects is reached.   
No more than 20% TNF-IR subjects will be enrolled in the study.   Subjects can be re- screened only once and no study- related re- screening procedure should be 
performed prior to written re -consent by [CONTACT_423]. Mis -randomization occurs when a subject 
who does not meet all eligibility criteria receives a randomization number in IRT in error; mis -
randomized subjects will be treated as screen failures and will not be re -screened. However, if 
the subject randomized in error was dosed then he/she will be discontinued. 
[COMPANY_001]  Confidential  Page 32  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
5.[ADDRESS_1027660] meet all  of the following criteria:  
1. Subject must be able to understand and communicate with the investigator, comply with 
the requirements of the study. and must give written, signed and dated informed consent before any study assessment is performed  
2. Male and non -pregnant, non- lactating female patients ≥ [ADDRESS_1027661] 6 months 
b. Onset before 45 years of age 
4. For subjects with AS: Diagnosis of AS with prior documented radiologic evidence (x- ray 
or radiologist’s report) fulfilling the Modified [LOCATION_001] criteria for AS  
5. For subjects with nr-axSpA:  
X-ray of SIJ negative (centrally read) for AS by [CONTACT_750627]  
a. Sacroiliitis on MRI (centrally read) with ≥ 1 SpA feature OR HLA -B-27 positive with 
≥2 SpA features AND  
b. Objective signs of inflammation at screening, evident by [CONTACT_750628] (centrally read) AND / OR hsCRP > ULN (as defined by [CONTACT_27681]) 
6. Active ax ial SpA assessed by [CONTACT_750629] ≥4 cm (0 -10 cm) at Baseline  
7. Spi[INVESTIGATOR_90150] #2 ≥ 4 cm (0 -10 cm) at Baseline  
8. Total back pain as measured by [CONTACT_8298] ≥ 40 mm (0- 100 mm) at Baseline  
9. Subjects should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or contraindications  
10. Subjects who are regularly taking NSAIDs (including COX- 1 or COX- 2 inhibitors) as part 
of their AS or nr- axSpA therapy are required to be on a stable dose for at least [ADDRESS_1027662] been inadequate respond ers to a TNF inhibitor (not 
more than one) will be allowed to enter into the study (not more than 20% per group). They must have experienced an inadequate response to previous or current treatment at an approved dose for at least [ADDRESS_1027663] one administration  of an anti-TNF agent. These subjects will undergo an appropriate 
wash -out period prior to randomization, if required 
a. 4 weeks for Enbrel
® (etanercept) – with a terminal half-life of 102 ± 
30 hours 
b. 8 weeks for Remicade® (infliximab) – with a terminal half -life of 8.0-9.5 days 
c. 10 weeks for Humira® (adalimumab) – with a terminal half -life of 10 -20 days 
(average 2 weeks)  
d. 10 weeks for Simponi® (golimumab) – with a terminal half- life of 11 -14 days 
e. 10 weeks for Cimzia® (certolizumab) – with a terminal half -life of 14 days 
[COMPANY_001]  Confidential  Page 33  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
12. Subjects taking methotrexate (MTX) (≤ 25 mg/week ) or sulfasalazine (≤ 3 g/day) are 
allowed to continue their medication and must have taken it for at least [ADDRESS_1027664] be on a stable dose of ≤10 mg/day prednisone or equivalent for at least [ADDRESS_1027665] x -ray or MRI with evidence of ongoing infectious or malignant process obtained 
within 3 months of screening and evaluated by a qualified physician 
3. Subjects taking moderate and high potency opi[INVESTIGATOR_2467] (e.g. methadone, hydromorphone, morphine) 
4. Presence of significant medical problems which at in vestigator’s discretion, will prevent 
the subject  from participating in the study, including but not limited to the following: 
Subjects with severely reduced kidney function (estimated glomerular filtration rate (eGFR) <29 ml/min/1.73m
2), history of renal trauma, glomerulonephritis, or patients with 
one kidney only, or a serum creatinine level exceeding 1.5 mg/dl (132.6 μmol/L)  
5. Any therapy by [CONTACT_90169]- articular injections (e.g. corticosteroid) within 4 weeks before 
Randomization 
6. Underlying conditions (including, but not limited to metabolic, hematologic, renal, 
hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opi[INVESTIGATOR_108989]/or places the subject  at unacceptable risk for receiving an immunomodulatory therapy  
7. Any medical or psychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would preclude 
the participant from adhering to the protocol or completing the study per protocol  
8. Active systemic infections during the last two weeks (exception: common cold) prior to 
randomization or any infection that reoccurs on a regular basis 
9. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by [CONTACT_5640] a pos itive purified protein derivative ([COMPANY_003]) skin test (the 
size of induration will be measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5 mm or according to local practice/guidelines) or a positive QuantiFERON TB- Gold test as i ndicated in the assessment schedule in Table [ADDRESS_1027666] may participate in the study if further work up (according to local practice/guidelines) establishes conclusively  that the subject has no evidence of 
active tuberculosis. If presence of latent tuberculosis is established, then treatment according to local country guidelines must have been initiated 
10. Past medical history of infection with HIV or hepatitis B prior to ra ndomization or active 
infection or on treatment for Hepatitis C at randomization  
[COMPANY_001]  Confidential  Page 34  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
11. History of lymphoproliferative disease or any known malignancy, or history of 
malignancy of any organ system treated or untreated within the past 5 years, regardless of whethe r there is evidence of local recurrence or metastases (except for skin Bowen’s 
disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed) 
12. Use or planned use of prohibited concomitant medication (see Section  6.2.2) 
13. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins) 
14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory test  
15. History or evidence of ongoing alcohol or drug abuse, within the last six months before randomization 
16. Screening total WBC count <3,000/μl, or platelets <100,000/μl or neutrophils  <1,500/μl or hemoglobin <8.5 g/dl (85 g/L) 
17. History of clinically significant liver disease or liver injury indicated by [CONTACT_250340], such as SGOT (AST), SGPT (ALT), alkaline phosphatase and serum 
bilirubin. The investigator should be guided by [CONTACT_4868]: 
• Any single parameter may not exceed 2 x the upper limit of normal (ULN). A single 
parameter elevated up to and including [ADDRESS_1027667] prior to randomization, to rule- out 
laboratory error.  
• If the total bilirubin concentration is increased above [ADDRESS_1027668] reacting bilirubin. In any case, serum 
bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L) 
18. Significant medical problems or diseases, including but not limited to the following:  
uncontrolled hypertension (≥160/95 mmHg), congestive heart failure ([LOCATION_001] Heart 
Association status of class III or IV), uncontrolled diabetes, or very poor functional status precluding ability to perform self- care 
19. Plans for administration of live vaccines during the study period or within 6 weeks prior to randomization 
20. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using effective methods of contraception during the 
entire study or longer if required by [CONTACT_109016] (e.g., 20 weeks in EU). Effective contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal l igation at least six weeks before taking study treatment. In 
case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_750642] 35  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
• Male sterilization (at least 6 months prior to screening). For female subjects on the 
study, the vasectomized male partner should be the sole partner for that subject  
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). For [LOCATION_006]: with spermicidal foam/gel/film/cream/ vaginal suppository  
• Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception 
• Placement of an in trauterine device or intrauterine system  
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_1027669] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_750643]. 
21. Active ongoing inflammatory diseases other than axSpA that might confound the evaluation of the benefits of secukinumab therapy, including inflammatory bowel disease or uveitis 
22. Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the subject unsuitable for the trial  
23. Use of other investigational drugs at the time of enrollment, or within [ADDRESS_1027670] has returned to baseline, whichever is longer; or longer if required by [CONTACT_427] 
24. History of hypersensitivity to any of the study drug constituents 
25. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor 
26. Previous treatment with any cell- depleting therapi[INVESTIGATOR_90156] -
CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)  
6 Treatment 
6.1 Study treatment  
6.1.1 Investigational and control  drugs 
[COMPANY_001] will supply the following study treatments:  
Investigational Treatment:  
• Secukinumab liquid in vial (LiV) for i.v. infusion provided in glass vials,  
 

[COMPANY_001]  Confidential  Page 36  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Reference T herapy: 
• Secukinumab placebo  for i.v. infusion provided in 5 mL LiV. 
The LiV glass vials are packed in double -blind (treatment period 1, up to and including Week 
12) and open label fashion (treatment period 2, from Week 16 onwards). For detailed 
instructions for storage, handling and administration of study treatment, please refer to the Pharmacist  Manual.  
The study medication will be labeled as follows: 
• Double blind Secukinumab Liquid in Vial will be labeled as AIN457  
Placebo.  
• Open label Secukinumab Liquid in Vial will be labeled as AIN457  
6.1.2 Additional study treatments 
No other treatment/s beyond investigational drug and control drug are included in this trial. 
6.1.3 Treatment arms/group 
At baseline, all eligible subjects will be randomized to one of the two treatment arms in a 1:1 
ratio via Interactive Response Technology (IRT): 
• Group 1: 200 AS  subjects and 50 nr-axSpA subjects ; These subjects will receive 
secukinumab  6 mg/kg i.v. at rando mization (i.e. BSL), followed by [CONTACT_750644] 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 
(exposure through Week 52). 
• Group 2: 200 AS  subjects and 50 nr-axSpA subjects ; These subjects will receive i.v. 
placebo at randomization (i.e. BSL) and at Weeks  4, 8, and 12, followed by [CONTACT_750645] 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52). 
All subjects will receive blinded treatment every four weeks starting  at baseline and until Week 
16. At Week 16, subjects from Group 1 will continue using secukinumab 3 mg/kg i.v. and subjects from Group 2 will start receiving secukinumab 3 mg/kg i.v. every four weeks (see Figure 3-1 ). 
Treatment will be provided open- label from Week 16 onwards, as all subjects will be receiving 
3 mg/kg i.v. every 4 weeks; however, the investigators, site personnel, subjects and monitors  will remain blinded to initial randomized group assignment. 
6.1.4 Treatment duration 
The planned duration of treatment is 52 weeks. Subjects may be discontinued from treatment earlier (see Section  9.1.1) due to unacceptable toxicity, dis ease progression and/or at the 
discretion of the investigator or the subject.  
6.2 Other treatment(s)  
No additional treatment beyond investigational drug is provided in this trial.  

[COMPANY_001]  Confidential  Page 37  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
6.2.[ADDRESS_1027671] to notify the study site about any new medications 
(including over -the-counter drugs, calcium and vitamins) administered after the subject was 
enrolled into the study. All medications (other than study treatment), procedures and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) must be recorded on the 
Prior and Concomitant medications or Procedures and Significant Non Drug Therapy eCRF. The reason, name [CONTACT_18467], procedure or non-drug therapy should be listed. 
Guidelines for the use of specific medications are provided below: Methotrexate (MTX)  
Subjects taking MTX (up to 25 mg/week) must be on a stable dose for at least [ADDRESS_1027672] be recorded on the 
corresponding eCRF page. 
Intra -articular corticosteroids are not permitted within the 4 weeks p receding randomization 
and up to Week 16. After Week 16, no more than 1 joint per 24- week period may be injected . 
No single injection should exceed 40 mg of triamcinolone (or equivalent) and the total dose of 
intra-articular corticosteroid may not exceed 80 mg of triamcinolone (or equivalent) during any 
52-week period. Injection of intra -articular steroids is not permitted within 8 weeks prior to 
Week 52. 
Non-steroidal anti -inflammatory drugs (NSAIDs) (including COX -1 or COX -2 
inhibitors), low strength opi[INVESTIGATOR_250314]/paracetamol  
Subjects on regular use of NSAIDs or paracetamol/acetaminophen should be on stable dose for 
at least 2 weeks before randomization to allow inclusion in the study. 
Subjects taking NSAIDs, low strength opi[INVESTIGATOR_750610] l/acetaminophen PRN within the 
2 weeks before randomization can continue to do so in the study; however, they have to refrain 
from any intake during at least the 24 hours before a visit with disease activity assessment. Regular dosing with low strength opi [INVESTIGATOR_750611].  
After the Week 16 assessments are completed, a change in the NSAID intake regimen is permitted.  
[COMPANY_001]  Confidential  Page 38  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Any change of the NSAID/paracetamol/acetaminophen treatment during the trial should be 
recorded on the corresponding eCRF page. 
6.2.[ADDRESS_1027673] study treatment administration.  
Table 6-1 Prohibited medication 
Medication  Washout period 
(before randomization)  Action  
(after randomization)  
Any biologic drugs, including but not limited to TNFα inhibitors, secukinumab, or 
other biologic drugs targeting 
IL-17 or IL- 17 receptor  
Etanercept  
Infliximab  
Adalimumab, golimumab, 
certolizumab  Biological immunomodulating 
agents > 3 different TNFα 
Inhibitors: never  
 
 
4 weeks  
8 weeks  
10 weeks  Discontinue investigational 
treatment  
Any cell-depleting therapi[INVESTIGATOR_750612] -
CD20 or investigational agents 
[e.g., alemtuzumab (Campath), 
anti-CD4, anti -CD5, anti -CD3, 
and anti -CD19]  Never  Discontinue investigational treatment  
Conventional 
synthetic  DMARDs (with the 
except ion of MTX and 
sulfasalazine) and ts -DMARDs 
including apremilast, tofacitinib, 
etc. 4 weeks  Discontinue investigational 
treatment  
Leflunomide  8 weeks  Discontinue investigational 
treatment  
Leflunomide with 
cholestyramine washout# 4 weeks  Discontinue inves tigational 
treatment  
Any investigational treatment or 
participation in any 
interventional trial  4 weeks or 5 half -lives 
(whichever is longer)  Discontinue investigational 
treatment  
Unstable dose of NSAIDs 
(including selective COX -1 and 
COX -2 inhibitors)  2 weeks  Dose adjustments allowed after 
Week  16 
Discontinuation of investigational treatment may 
be required on a case by [CONTACT_17878].  
Analgesics other than NSAIDs, paracetamol/acetaminophen, 
and low strength opi[INVESTIGATOR_232097]+ 2 weeks  Discontinue investigational 
treatment  
[COMPANY_001]  Confidential  Page 39  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Medication  Washout period  
(before randomization)  Action  
(after randomization)  
Systemic corticosteroids > 10 
mg prednisone equivalent (until 
Week 16)*  2 weeks  If administered due to a 
medical urgency unrelated to 
the patient’s arthritis, study treatment should be interrupted 
until the steroid is  discontinued. 
If not administered for a 
medical urgency or for use 
related to the patient’s arthritis, then discontinuation of 
investigational treatment may 
be required on a case by [CONTACT_750646] ≤ 10 mg 
prednisone equivalent (until 
Week 16)*  2 weeks  
Discontinue investigational 
treatment (Dose adjustments 
allowed after Week  16) 
Discontinuation of 
investigational treatment may 
be required on a case by [CONTACT_17878].  
Intra-articular corticosteroids 
injections (until Week  16)* 4 weeks  Discontinue investigational 
treatment  
Intramuscular or intravenous corticosteroid treatment  4 weeks  
Discontinuation of 
investigational treatment may be required on a case by [CONTACT_750647]  6 weeks  If administered due to a medical urgency, study treatment should be interrupted 
for 4 months. If administered 
not for a medical urgency then discontinue investigational 
treatment  
* See details about corticosteroid management in Section  6.2.1 . 
+ Regular dosing with low strength opi[INVESTIGATOR_750611].  
#In case of leflunomide treatment, a drug wash-out of [ADDRESS_1027674] be performed.  Another wash -out 
procedure might also be considered. Cholestyramine could be given orally to wash- out the drug at a 
dose of 8 g t.i.d. Cholestyramine reduced plasma levels of the active leflunomide metabolite by [CONTACT_3450] 40 % in 24 hours and by 49 % to 65 % in [ADDRESS_1027675] receives 8 g t.i.d. for 11 days he/she can be safely randomized [ADDRESS_1027676] is experiencing either no benefit from participation in 
the trial or worsening / exacerbation of his/her disease.  
Rescue medication should not be used before  completion of Week 16 assessments (see Table 
8-1). Although no subject will be restricted from receiving necessary rescue medications for 
[COMPANY_001]  Confidential  Page 40  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
lack of benefit or worsening of disease, if rescue with  prohibited biologics (as described in 
Section  6.2.2) occurs prior to completion of Week [ADDRESS_1027677] will be free to discontinue participation in the study at any time. 
Changes in concomitant therapy with NSAIDs are permitted after Week 16 assessments as per 
investigator’s clinical judgment. After Week 16, the dose and regimen of other concomitant 
medications may be adjusted slowly at the investigator’s discretion and record ed appropriately 
on the CRF page. 
Any use of rescue medication must be recorded in the Prior/Concomitant medications eCRF.  
6.[ADDRESS_1027678] Number (Subject No.) that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject throughout his/her entire participation in the trial. The Subject No. consists of the Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential subject number suffixed to it, so that each subject is numbered uniquely across the entire database. Once assigned to a subject, the Subject No. will not be reused. Upon signing the informed consent form, the subject is assigned to the next sequential Subject No. available.   
6.3.2 Treatment assignment, randomization  
At BSL  visit,  all eligible subjects will be randomized via Interactive Response Technology 
(IRT) to one of the treatment arms. The investigator or his/her delegate will contact [CONTACT_201051]/exclusion criteria. The IRT will assign a randomization number to the subject, which will be used to link the subject to a treatment arm and will  specify a unique medication number for the first package of study treatment to be 
dispensed to the subject.  The randomization number will not be communicated to any of the 
site staff.  
Starting at Week 16, subjects who have been randomized to placebo at ba seline will receive 
secukinumab 3 mg/kg i.v. up to Week 48. Although the investigator, site personnel and subjects are unblinded to current treatment assignment after Week 16 (as all subjects will be on 
secukinumab 3 mg/kg i.v starting at Week 16), origina l treatment assignment, as per baseline 
randomization, will remain blinded to the subject, investigator, and site personnel until after 
final database lock and analyses.  
All efficacy and safety assessments should be done prior  to calling IRT.  
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from subjects and investigator staff. A subject randomization list will be produced by [CONTACT_6609] a validated system that  automates 
the random assignment of subject numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication 
[COMPANY_001]  Confidential  Page 41  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
numbers. A separate medication list will be produced  by [CONTACT_750648] e responsibility of [COMPANY_001] 
Global Clinical Supply (GCS) using a validated system that automates the random assignment 
of medication numbers to packs containing the study treatment. 
The subjects will be stratified at randomization according to disease con dition (i.e. AS or nr -
axSpA). Not more than 20% of randomized subjects will be TNF - IR to ensure a representative 
subject population for the assessment of efficacy and safety.  
The randomization scheme for subjects will be reviewed and approved by a member of the 
Randomization Office.  
6.4 Treatment blinding  
This is a double- blind, randomized treatment trial.  
Subjects, investigators, investigator staff and persons performing the assessments, will remain blind to the identity of the treatment from the time of randomization until database lock, using 
the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by [CONTACT_250345], (2) the  identity of the treatments will be concealed by [CONTACT_750649], filled with secukinumab or placebo  that are identical in appearance.   
The bioanalyst will have access to the randomization list to facilitate analysis of the PK  
 (i.e. to avoid the unnecessary analysis of placebo samples). Whenever 
needed or requested by [CONTACT_6098], the bioanalyst will share information from PK measurements before clinical database lock in a blinded fashion with the pharmacokineticist.  
Starting at Week 16, subjects who have been randomized to placebo at baseline will start receiving secukinumab 3 mg/kg i.v. every four weeks up to Week 48. Although subjects, investigators, investigator staff and persons performing the  assessments are unblinded to current 
treatment assignment after Week 16 (as all patients will be on secukinumab 3 mg/kg i.v. at Week 16), original treatment assignment, as per baseline randomization, will remain blinded to subjects, investigator staff and  persons performing the assessments until after final database 
lock and analyses. 
Unblinding will occur in the case of subject emergencies (see Section  6.6.3) and at the 
conclusion of the study. Unblinding of the Global core CTT members will also occur at the time of the primary analysis 
database lock (see Section  12.7).  
The hsCRP results from samples collected during the treatm ent period will be revealed to sites 
only after the database lock and analyses are completed. The hsCRP results from samples collected during the treatment period 1 will be revealed to  Global core  CTT members  at the 
time of the  primary interim analysis database lock.  
6.5 Dose escalation and dose modification  
Dose modifications of the investigational study drug are not permitted.  

[COMPANY_001]  Confidential  Page 42  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
6.5.1 Dose escalation guidelines 
With the proposed i.v. regimen anticipated to provide exposures of secukinumab similar to the 
Cavg and C max achieved with 300 mg s.c. and C trough consistently above those achieved by 150 
mg s.c., dose escalations will not be provisioned for in this study.  
[IP_ADDRESS] Starting dose  
The starting dose at BSL for the active arm in the study will be secukinumab 6 mg/kg. The 
placebo group will receive as starting dose at BSL an appropriate infusion volume matching secukinumab 6 mg/kg. 
6.5.2 Dose modifications  
Study treatment interruptions are not permitted with the following exceptions:  
• If, in the opi[INVESTIGATOR_871], a subj ect is deemed to be placed at a significant 
safety risk unless dosing is temporarily interrupted. In such cases study treatment should 
be interrupted only during the time that this risk is present and ongoing. Study treatment can be restarted at the next scheduled visit after resolution of the safety risk.  
• If any prohibited medication described in Table [ADDRESS_1027679], etc., should be consulted as deemed necessary. 
[IP_ADDRESS] Follow up on potential drug- induced liver injury (DILI) cases 
An increase in transaminase increase combined with total bilirubin (TBIL) increase may be 
indicative of potential DILI and should be considered as clinically important events. 
The threshold for potential DILI may depend on the subject’s baseline AST/ALT and TBIL 
value; subjects meeting any of the following criteria will require further follow -up as outlined 
below:  
• For subjects with normal ALT and AST and TBIL value at baseline: AST or ALT > 3.[ADDRESS_1027680] combined with TBIL > 2.[ADDRESS_1027681] 
• For subjects with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x baseline AND > 3.[ADDRESS_1027682]] OR [AST or ALT > 8.[ADDRESS_1027683]], combined with [TBIL > 2 x baseline AND > 2.[ADDRESS_1027684]] 
Medical review needs to ensure that liver test elevations are not caused by [CONTACT_15014], defined as ALP elevation > 2.[ADDRESS_1027685] with R value < 2 in subjects without bone metastasis, or elevation 
of ALP liver fraction in subjects with bone metastasis.  
[COMPANY_001]  Confidential  Page 43  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury.  
In the absence of cholestasis, these subjects should be immediately discontinued from study treatment, and repeat LFT testing as soon as possible, preferably within 48 hours from the awareness of the abnormal results. The evaluation should include laboratory tests, detailed history, physical assessment, and the possibility of liver metastasis or new liver lesions, obstructions/compressions, etc.  
1. Laboratory tests should include  ALT, AST, albumin, creatine kinase, TBIL, direct and 
indirect bilirubin, GGT, prothrombin time (PT)/INR, and alkaline phosphatase. 
2. A detailed history, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, and history of any pre -existing liver 
conditions or risk factors, should be collected. 
3. Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary tract) 
may be warranted.  
4. Obtain PK sample as close as possib le to last dose of secukinumab. 
5. Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), autoimmune hepatitis or liver biopsy may be considered as clinically indicated or after consultation with specialist/hepatologist.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medically significant,” and thus, meet the definition of SAE and should reported as SAE using the term “potential drug- induced liver injury.” All events should be followed up with the outcome clearly 
documented. 
6.[ADDRESS_1027686]’s safety and the validity of the study. The subject should be instructed to contact [CONTACT_087]/she is unable for any reason to attend a study visit as scheduled.  
Compliance is expected to be 100%, unless temporary interruption is needed for safety reasons 
as described in Section  6.5.[ADDRESS_1027687] eCRF page.  
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all subjects 
treated with secukinumab, as detailed in pharmacokinetics section (see Section  8.5.5 ). 
[COMPANY_001]  Confidential  Page 44  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
6.6.2 Recommended treatment of adverse events 
Medication used to treat adverse events (AEs) must be recorded on the appropriate CRF. 
6.6.[ADDRESS_1027688], he/she must provide the requested subject identifying information and confirm the nece ssity to break the treatment code 
for the subject. The investigator will then receive details of the investigational drug treatment for the specified subject and a fax or email confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the study team that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investi gator 
will provide to the subject:  
• protocol number 
• study drug name 
• subject number 
In addition, oral and written information to the subject must be provided on how to contact [CONTACT_093]'s backup in cases of emergency, or when he/she is unavailable, to ensure that un-
blinding can be performed at any time. 
Study drug must be discontinued after emergency unblinding . 
6.7 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational 
and control drugs section (see Section  6.1.1).  
Detailed instructions for storage, handling and administration of the study treatment are included in the Pharmacist Manual. 
A unique medication number is printed on the study medication label. Investigator staff will identify the study medication kits to dispense to the subject by [CONTACT_37246](s). The study medication has a 2- part label (base 
plus tear -off label), immediately before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source document. 
[COMPANY_001]  Confidential  Page 45  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
6.7.1 Handling of study treatment and additional treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels and in the Investigator’s Brochure. Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] CO Quality Assurance.  
Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the study treatment but no information about the subject except for the medication number . 
The inves tigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_30798].  
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] a ddress provided in the investigator 
folder at each site.  
[IP_ADDRESS] Handling of additional treatment  
The following non- study treatment will be monitored specifically:  
• Stable doses of MTX, sulfasalazine and/or NSAIDS and acetaminophen/paracetamol as applicable (see Section  6.2.1) 
7 Informed consent procedures  
Eligible subjects may only be included in the study after providing (witnessed, where required 
by [CONTACT_6617]), IRB/IEC -approved informed consent. 
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study to the extent possible given his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is  considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_6619]/IEC.  
Information about common side effects already known about the investigational drug can be found in the Investigator's Brochure (IB). This information will be included in the subject 
[COMPANY_001]  Confidential  Page 46  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
informed consent and should be discussed with the subject during the study as needed. Any new 
information regarding the safety profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New informatio n might require an update to the informed consent 
and then must be discussed with the subject. 
Women of child -bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception requirements. 
A
 copy of the approved version of all consent forms must be provided to [COMPANY_001]/sponsor after 
IRB/IEC approval.  
Subjects will be asked to complete optional questionnaires to provide feedback on their clinical trial experience.  
8 Visit schedule and assessments 
Assessment schedule ( Table 8 -1) lists all of the assessments when they are performed. All data 
obtained from these assessments must be supported in the subject’s source documentation. 
Subjects should be seen for all visits/ assessments as outlined in the assessment schedule ( Table 
8-1) or as close to the designated day/time as possible.  
The study treatment should not be administered within less than [ADDRESS_1027689] study treatment, a t which time all of the assessments listed for the 
final visit will be performed (corresponding to the last visit for the subject’s current period of treatment (treatment period 1 or 2): i.e., Week 16 or Week 52). At this final visit, all dispensed investi gational product should be reconciled, and the adverse event and concomitant 
medications recorded on the CRF. A follow -up visit is to be done [ADDRESS_1027690] them or a knowledgeable informant by [CONTACT_683506]. 
For Patient Report Outcomes (PROs) Section  16.5 provides guidance for completion of the 
questionnaires.  

[COMPANY_001]  Confidential  Page 47  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Table 8-1 Assessment Schedule 
Period  Screening  Extension 
Screening  Treatment Period 1  Treatment Period 2  Follow -
up 
Visit Name  [CONTACT_750677] 11 Screening  
visit 2  Baseline 
(BSL)  Wee
k 4 Wee
k 8 Wee
k 12 Wee
k 16 Wee
k 20 Wee
k 24 Wee
k 25 Wee
k 28 Wee
k 32 Wee
k 36 Wee
k 40 Wee
k 44 Wee
k 48 Wee
k 52 Week 60  
Days  -70 to -29 -28 to -1 - 28 56 84 112 140 168 175 196 224 252 280 308 336 364 420 
Informed consent  X                                   
Inclusion / Exclusion 
criteria2,3 X X X                               
Medical 
history/current 
medical conditions2 X X X                               
axSpA and nr -axSpA 
assessment and history of extra -axial 
involvement4,5 X                                   
Demography  X                                   
X-ray (sacroiliac 
joints)6 X                                   
MRI (sacroiliac 
joints)6   X                                 
Cardiovascular 
medical history      X                               
Smoking history      X                               
Physical 
Examination8   S S S S S S S S S S S S S S S S S 

[COMPANY_001]  Confidential  Page 48  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Period  Screening  Extension 
Screening  Treatment Period 1  Treatment Period 2  Follow -
up 
Visit Name  [CONTACT_750677] 11 Screening  
visit 2  Baseline 
(BSL)  Wee
k 4 Wee
k 8 Wee
k 12 Wee
k 16 Wee
k 20 Wee
k 24 Wee
k 25 Wee
k 28 Wee
k 32 Wee
k 36 Wee
k 40 Wee
k 44 Wee
k 48 Wee
k 52 Week 60  
Days  -70 to -29 -28 to -1 - 28 56 84 112 140 168 175 196 224 252 280 308 336 364 420 
Body Height    X                                 
Body Weight & BMI9   X X X X X X X X   X X X X X X   X 
Vital Signs    X X X X X X X X X X X X X X X X X 
[COMPANY_003] skin test or 
QuantiFERON TB -
Gold test10   
X                                 
Chest X -ray or 
MRI11,[ADDRESS_1027691] 
(serum)[ADDRESS_1027692] 
(urine)14,15     S S S S S S S   S S S S S S S S 
12-Lead ECG  S                                   
Randomization      X                               
PK blood collection      X16 X16 X16   X17   X16 X           X16 X X 
Study drug 
administration      X X X X X X X   X X X X X X     

[COMPANY_001]  Confidential  Page 49  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Period  Screening  Extension 
Screening  Treatment Period 1  Treatment Period 2  Follow -
up 
Visit Name  [CONTACT_750677] 11 Screening  
visit 2  Baseline 
(BSL)  Wee
k 4 Wee
k 8 Wee
k 12 Wee
k 16 Wee
k 20 Wee
k 24 Wee
k 25 Wee
k 28 Wee
k 32 Wee
k 36 Wee
k 40 Wee
k 44 Wee
k 48 Wee
k 52 Week 60  
Days  -70 to -29 -28 to -1 - 28 56 84 112 140 168 175 196 224 252 280 308 336 364 420 
Prior and 
Concomitant Medication and Prior 
or Concomitant non-
drug 
therapi[INVESTIGATOR_014]/procedures  X Update as necessary  
Wash- out evaluation / 
instructions  S                                   
Adverse events/SAEs 
(including injection 
site reactions)18 X Update as necessary  
Patient’s global assessment of 
disease activity (VAS)      
X X X X X X X X X X X X X X X X 
Patient’s assessment of back pain intensity 
(VAS)      
X X X X X X X X X X X X X X X X 
BASFI      X X X X X X X X X X X X X X X X 
BASDAI      X X X X X X X X X X X X X X X X 
SF-36      X   X   X   X               X   
ASQoL      X   X   X   X               X   

[COMPANY_001]  Confidential  Page 50  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Period  Screening  Extension 
Screening  Treatment Period 1  Treatment Period 2  Follow -
up 
Visit Name  [CONTACT_750677] 11 Screening  
visit 2  Baseline 
(BSL)  Wee
k 4 Wee
k 8 Wee
k 12 Wee
k 16 Wee
k 20 Wee
k 24 Wee
k 25 Wee
k 28 Wee
k 32 Wee
k 36 Wee
k 40 Wee
k 44 Wee
k 48 Wee
k 52 Week 60  
Days  -70 to -29 -28 to -1 - 28 56 84 112 140 168 175 196 224 252 280 308 336 364 420 
PSQI      X X X X X X               X X   
High sensitivity C-
Reactive protein 
(hsCRP)    
X X X X X X   
X X   
X   
X     
X X 
HLA-B27   X                                 
Lipid profile19     X   X   X   X               X   
Cardiovascular panel      X       X   X               X   
Trial Feedback 
Questionnaire (TFQ)      X               X             X 
Treatment period 1 
completion form              X                       
Treatment period 2 
completion form                                  X   
Follow -up completion 
form                                   X 

[COMPANY_001]  Confidential  Page 51  
Clinical Trial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Period  Screening  Extension 
Screening  Treatment Period 1  Treatment Period 2  Follow -
up 
Visit Name  [CONTACT_750677] 11 Screening  
visit 2  Baseline 
(BSL)  Wee
k [ADDRESS_1027693]’s washout period ≤ 4 weeks, Screening visit 1 (SV1) and Screening visit 2 (SV2) can b e performed on the same day.  
[ADDRESS_1027694]’s report must be kept in the source documentation.  
4 Extra -axial involvement such as uveitis, psoriasis, inflammatory bowel disease, dactylitis, enthesitis, peripheral arthritis.  
5 The "modified [LOCATION_001] criteria for AS" eCRF page will have to be completed for axSpA and nr -axSpA subjects.  
6 Only applicable for nr- axSpA subjects.  
 
8 These assessments are source documentation only and will not be entered into the eCRF. However, data regarding to which inclu sion/exclusion 
criteria are not met are captured on the Inclusion/Exclusion eCRF.  After the baseline visit, the investigator should do an abbreviated physical exam 
focusing on relevant clinical areas.  
[ADDRESS_1027695] meets inclusion/exclusion criteria in order to minimize unnecessary exposure to radiation. The x -ray may be replaced by [CONTACT_750650].  
12 These assessments are source documentation only and will not be entered into the eCRF. However, data regarding to which inclusion/exclusion 
criteria are not met are captured on the Inclusion/Exclusion eCRF.  
13 Hepatitis B and/or hepatitis C and/or HIV serology testing to be performed during screening period only if required as per local me dical practice or 
local regulations prior to initiation of therapy. These assessments will be documented in source records only and will not be entered into the eCRF.  
[ADDRESS_1027696] -dose.  
17 At pre -dose.  
18 AEs / SAEs occurring after the subject has signed the informed consent must be captured on the appropriate eCRF page.  
[ADDRESS_1027697] be obtained fasting.  
  

[COMPANY_001]  Confidential  Page 52  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.[ADDRESS_1027698] screening visit,  initial 
assessments will be performed as outlined in Table 8 -1. At that visit the duration of the washout 
period will be determined. The second screening visit will be performed as follows:  
• If the washout period is ≤ 4 weeks the investigator should proceed directly to visit 2 on the same day and complete all assessments  
• If the washout period is more than [ADDRESS_1027699] will be instructed to initiate necessary washout regimen and return for visit 2 in the next 4 weeks prior to randomization (i.e., in all cases, Visit 2 should not happen earlier than 4 weeks prior to randomization). 
If subjects do not have a chest X -ray available within [ADDRESS_1027700] meets inclusion/exclusion criteria in order to minimize unnecessary exposure to radiation.The X -ray assessment may be replaced by [CONTACT_750650].  
All subjects evaluated at visit 1 and 2 for Inclusion/Exclusion criteria should not be screen failed on the basis of a medication requiring washout, unless the subject will be unable to complete the washout in the appropriate time frame before randomization.  
8.1.1 Information to be collected on screening failures  
Subjects who sign an informed consent form and subsequently found to be ineligible prior to randomization will be considered a screen failure. The reason for screen failure should be recorded on the appropriate Case Report Form. The demographic information, informed consent, and I nclusion/Exclusion pages must also be completed for screen failure subjects. No 
other data will be entered into the clinical database for subjects who are screen failures, unless the subject experienced a serious adverse event during the screening phase (see SAE Section  10.1.2 for reporting details). The CRF for adverse events (AEs) should be completed 
for any Serious Adverse Events (SAEs) that occurred during the screening period. Adverse events that are not SAEs will be followed by [CONTACT_90200].   
If the subject fails to be randomized, the IRT must be notified within [ADDRESS_1027701] was not randomized. 
Subjects who are randomized and fail to start treatment, e.g. subjects randomized in error, will 
be considered an early terminator. The reason for early termination should be recorded on the appropriate Case Report Form. 
Subjects who are prematurely withdrawn from the stud y will not be replaced. 
[COMPANY_001]  Confidential  Page 53  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.1.[ADDRESS_1027702] number. For 
all re -screened subjects, th e investigator/qualified site staff will record if the subject was re -
screened on the re -screening CRF and the original screening number the subject was issued 
prior to the current screening number. The date of the new informed consent signature [CONTACT_750678]. For re -
screening, all screening assessments must be performed per protocol, except the tuberculosis (TB) work up (if applicable). If the date of the TB work up is less than 12 weeks from the projected baseline date, then it is not required that the TB work up be repeated; however, the re-screened subject must repeat [COMPANY_003] skin test or the QuantiFERON TB -Gold performed by [CONTACT_19979]. 
8.[ADDRESS_1027703] demographics/other baseline char acteristics  
Subject demographic and baseline characteristics data to be collected on all subjects and to be recorded in the eCRF include: 
• Age, sex, race, ethnicity and source of subject referral  
• Relevant axSpA and general medical history/current medical co ndition data until the start 
of study treatment, history of extra- axial involvement (uveitis, psoriasis, inflammatory 
bowel disease, dactylitis, enthesitis, peripheral arthritis), number and type of previous 
DMARDs used, date of diagnosis of axSpA, previous axSpA therapi[INVESTIGATOR_014], functional status class according to the [LOCATION_001] criteria, cardiovascular medical history and smoking history  
Whenever possible, diagnoses and not symptoms will be recorded. 
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with CRF.  
8.3 Efficacy  
• Assessment of SpondyloArthritis International Society (ASAS) response criteria; 
ASAS40, ASAS20, ASAS 5/6 and ASAS partial remission  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
  
• Bath Ankylosing Spondylitis Functional Index (BASFI) 
• Patient’s global assessment of disease activity (VAS)  
• Patient’s assessment of back pain intensity (VAS)  
  
• Medical Outcome Short Form Health Survey (SF-36) Version 2 (Acute Form) 
• Ankylosing Spondylitis Quality of Life (ASQoL) 
• High sensitivity C- Reactive Protein (hsCRP)  
  

[COMPANY_001]  Confidential  Page 54  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
  
•
 Ankylosing Spondylitis Disease Activity Score (ASDAS)-C- Reactive Protein (CRP)  and 
ASDAS response categories  
  
  
• Sleep improvement (  sleep PROs) 
8.3.1 Assessment of SpondyloArthritis International Society criteria (ASAS)  
The ASAS response measures consist of the following assessment domains ( Sieper  et al 2009).  
Main ASAS domains: 
1. Patient’s global assessment of disease activity measured on a VAS scale 
2. Patient’s assessment of back pain, represented by [CONTACT_750651] p ain scores, 
both measured on a VAS scale 
3. Function represented by [CONTACT_90203] [ADDRESS_1027704] 2 questions on the 6-question BASDAI as measured by [CONTACT_750652]: 
 
2. C-reactive protein (acute phase reactant)  
[IP_ADDRESS] ASAS Response Criteria- 40% (ASAS40)  
ASAS40 response is defined as a ≥40% improvement and an absolute improvement from baseline of ≥20 units (range 0–100) in ≥ 3 of the following 4 domains: back pain [10 cm visual analogue scale (VAS)], patient global assessment of disease activ ity (10 cm VAS), physical 
function (BASFI; range 0–100) and inflammation (mean score of items 5 and 6 of the BASDAI; both 10 cm VAS) without any worsening in the remaining domain. 
[IP_ADDRESS] ASAS Response Criteria- 20% (ASAS20)  
The ASAS Response Criteria (ASAS20) is defined as an improvement of ≥20% and ≥[ADDRESS_1027705] three of the four main domains and no worsening of ≥20% and ≥1 unit 
on a scale of 10 in the remaining domain. 
[IP_ADDRESS] ASAS 5/6 improvement criteria  
The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six 
domains. 
[IP_ADDRESS] ASAS partial remission criteria  
The ASAS partial remission is defined as a value not above 2 units in each of the four main 
domains on a scale of 10. 

[COMPANY_001]  Confidential  Page 55  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.3.2 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
BASDAI consists of a 0 through 10 scale ([ADDRESS_1027706] 
problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS: 
1. Fatigue 
2. Spi[INVESTIGATOR_18172] 
3. Peripheral joint pain / swelling  
4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments)  
5. Morning stiffness duration 
6. Morning stiffness severity  
To give each symptom equal weight, the mean (average) of the two scores relating to morning 
stiffness is taken into account (questions 5 and 6). The resulting 0 to 10 score is added to the scores for questions 1 through 4. The resulting 0 to 50 score is divided by 5 to give a final 0 – [ADDRESS_1027707] suboptimal control of the disease and subjects 
with scores of 4 or greater are usually good candidates for either a change in their medical therapy or enrollment in clinical trials evaluating new drug therapi[INVESTIGATOR_90159]. BASDAI is a quick and simple index taking between 30 seconds and 2 minutes to complete. 
  
 
8.3.4 Bath Ankylosing Spondylitis Functional Index (BASFI)  
The Bath Ankylosing Spondylitis Functional Index is a set of [ADDRESS_1027708] 8 questions consider 
activities related to functional anatomy. The final 2  questions assess the subjects’ ability to cope 
with everyday life. A 0 through 10 scale (captured as a continuous VAS) is used to answer the 
questions. The mean of the te n scales gives the BASFI score – a value between 0 and 10. 
8.3.5 Patient’s global assessment of disease activity (VAS)  
The patient’s global assessment of disease activity will be performed using a 100  mm VAS 
ranging from none to very severe in response to the question "How active was your disease on 
average during the last week?”.  
8.3.6 Patient’s assessment of back pain intensity (VAS)  
The patient’s assessment of back pain will be performed using a 100  mm VAS ranging from no 
pain to unbearable pain in response to the question “Based on your assessment, please indicate 
what is the amount of back pain at night that you experienced during the last week?” and “Based on your assessment, please indicate what is the amount of back pain at any time that 
you experienced during t he last week? ”  For ASAS calculation the total back pain will be used. 

[COMPANY_001]  Confidential  Page 56  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
8.3.
8 Medical Outcome Short Form Health Survey (SF- 36) Version 2 (Acute 
Form)  
The Medical Outcome Short Form Health Survey is a widely used and extensively studied 
instrument to measure health -related quality of life among healthy patients and patients wi th 
acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role -Physical, Bodily Pain, General Health, Vitality, Social Functioning, 
Role -Emotional, and Mental Health ( Ware and Sherbourne 1992). Two overall summary 
scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed  (McHorney  et al 1993 ). The SF- 36 has proven useful in monitoring 
general and specific populations, comparing the relative burden of different disease, differentiating the health benefits pr oduced by [CONTACT_506001], and in screening individual 
patients.  
The purpose of the SF -36 in this study is to assess the health -related quality of life  (HRQoL) of 
patients. Given the acute nature of this disease, version 2, with a 1 -week recall period , will be 
used in this study. 
8.3.9 Ankylosing Spondylitis Quality of Life (ASQoL)  
The Ankylosing Spondylitis Quality of Life is a self -administered questionnaire designed to 
assess health -related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL 
contains 18 items with a dichotomous yes/no response option. A single point is assigned for 
each "yes" response and no points for each "no" response, resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower scores indicate better quality of life. Items include an assessment of mobility/energy, self -care and mood/emotion. The recall 
period is "at the moment".  
The purpose of the ASQoL is to assess the disease specific QoL of patients in thi s study. 

[COMPANY_001]  Confidential  Page 57  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.3.10 High Sensitivity C -reactive protein (hsCRP)  
This assessment will be performed in order to identify the presence of inflammation, to 
determine its severity and to monitor the response to treatment.  
Since the results of this test may unblind the stu dy personnel to treatment groups, results from 
the central lab will be provided for screening and baseline only. The hsCRP results from samples collected during the treatment period will be revealed following database lock only.  
8.3.
13 ASDAS- CRP and ASDAS response categories 
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity  in AS.  
ASDAS -CRP will be utilized to assess the disease activity status. Parameters used for the 
ASDAS include: total back pain (BASDAI question 2), the patient global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and C- reactive protein (CRP) in mg/L (Lukas et  al 2009).  
Disease activity states: inactive disease, moderate disease activity, high disease activ ity, and 
very high disease activity. The 3 values selected to separate these states are: <1.3 between inactive disease and moderate disease activity; <2.1 between moderate disease activity and high disease activity; and >3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores are a change ≥1.1 unit for “minimal clinically important improvement” and a change ≥2.0 units for “major improvement” ( Machado  et al 2011 ). 

[COMPANY_001]  Confidential  Page 58  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  

[COMPANY_001]  Confidential  Page 59  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.3.16 Sleep improvement  
To measure improvement in sleep and reduction in nocturnal awakening, subjective sleep PROs 
 Pi[INVESTIGATOR_750613]; PSQI) will be used  
 
[IP_ADDRESS] Sleep PROs  
Patients with AS also report chronic and extensive sleep disturbance due to pain and stiffness 
during the night ( Leverment  et al 2017). Often patients get out of bed and walk around during 
the night to reduce pain and stiffness, which can lead to daytime fatigue ( Rudwaleit  et al 2006). 
In patients with AS, poor quality sleep is strongly correlated with increased pain, lower quality 
of life, higher depressed mood, higher disease activity and reduced physical function (Batmaz  et al 2013). Additionally, there is a general lack of data to investigate associations 
between sleep disturbance and daytime fatigue levels in AS.  
To study the effect of secukinumab on AS related sleep disturbance, the subjective sleep PRO’s in Section  [IP_ADDRESS].1 and Section  [IP_ADDRESS].2 will be used.  

[COMPANY_001]  Confidential  Page 60  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
[IP_ADDRESS].2 Pi[INVESTIGATOR_2272] (PSQI)  
The Pi[INVESTIGATOR_33563] a self -report questionnaire that assesses sleep quality over 
a 1-month time interval. Consisting of [ADDRESS_1027709] 
of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleepi[INVESTIGATOR_88794], and daytime dysfunction. 
Each item is weighted on a 0–[ADDRESS_1027710] measures used across all axSpA trials and are required for regulatory filing.  
8.4 Safety  
Evaluation of al l AEs and SAEs including injection site reactions, electrocardiograms (ECGs), 
physical examination, vital signs and laboratory assessments will occur.
All blood dr aws and safety assessments should be done prior to study treatment administration. 
Appropriate safety assessments (e.g. evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered.  
• Physical examination  
• Vital signs  
• Height and weight  
• QuantiFERON TB- Gold test or [COMPANY_003] skin test  
• Hepatitis and human immunodeficiency virus (HIV) screen 
• Laboratory evaluations (Hematology, clinical chemistry, lipid panel, cardiovascular panel, urinalysis and pregnancy test) 
• Evaluation of AE/ SAE’s  
• Electrocardiogram  
• Local tolerability (Injection site reactions)  
• Pregnancy and assessment of fertility  
• Tolerability of secukinumab  
  
Table 8-3 Assessments & Specifications 
Assessment  Specification  

[COMPANY_001]  Confidential  Page 61  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Physical  A complete physical examination of the subject 
will be performed according to the schedule 
defined in Table 8-1  and will include the 
examination of general appearance, hydration 
status, skin, neck (including thyroid), eyes, ears, 
nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular, and 
neurological. If indicated based on medical 
history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be 
performed.  Information for all physical 
examinations must be included in the source 
documentation at the study site. Clinically 
relevant findings that are present prior to signing 
informed consent form must be recorded on the appropriate CRF that captures medical history 
screen on the patient CRF. Significant findings 
that occur after signing informed consent form which meet the definition of an Adverse Event 
must be recorded as an adverse event.  
Vital signs  Vital signs will include blood pressure and pulse rate measurements after [ADDRESS_1027711] in sitting 
position. If possible, vital signs assessments 
should be performed by [CONTACT_750653].  
Height and weight  Height in centimeters (cm) and body weight, to 
the nearest 0.1 kilogram (kg), in indoor clothing 
but without shoes, will be measured.  If possible, 
body weight assessments should be performed 
by [CONTACT_750654].  
8.4.[ADDRESS_1027712] may participate in the study if further work up (according to 
local practice/guidelines), establishes conclusively that the subject has no evidence of active tuberculosis, OR, if presence of latent tuberculosis is established, then treatment according to local country guidelines  must have been initiated prior to enrollment.  
[IP_ADDRESS] A QuantiFERON TB- Gold test  
A QuantiFERON TB- Gold test is to be performed at the second screening visit and the results 
to be known prior to randomization to determine the subject’s eligibility for the trial. T he test 
will be used to screen the subject population for latent tuberculosis infection. 
The test will be analyzed by [CONTACT_2237]. Details on the collection, processing and 
shipment of samples and reporting of results by [CONTACT_2237] a re provided in the 
laboratory manual.  
[COMPANY_001]  Confidential  Page 62  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
[IP_ADDRESS] [COMPANY_003] skin test  
A [COMPANY_003] skin test is to be performed at screening and read before randomization to determine the 
subject’s eligibility for the trial, if a QuantiFERON test is not performed. The test dose is bioequivalent to [ADDRESS_1027713] superficial layer under the skin. If given correctly, the injection should ra ise a small wheal of 
about 5 mm, which resolves within 10-15 minutes. 
Because the reaction (induration), will take 48-[ADDRESS_1027714]. A reaction is measured in millimeters of induration (hard swelling) at the site. A [COMPANY_003] skin induration ≥5 mm (or according to local practice/guidelines) is interpreted as a positive resul t. 
8.4.2 Hepatitis and human immunodeficiency virus (HIV) screen  
Screening for hepatitis and HIV is optional, based on the judgment of the investigator or if required by [CONTACT_427]. If hepatitis testing is performed, testing will include hepatitis B surfa ce antigen (HBsAg) and anti -HCV antibodies. If HIV testing is performed, positive HIV 
screening will be confirmed by a second technique available at the respective local laboratory, e.g., Western blot. 
8.4.3 Laboratory evaluations  
A central laboratory will be us ed for analysis of all specimens listed below (except urinalysis). 
Details on the collection, shipment of samples and reporting of results by [CONTACT_750655]. For the identification of clinically notable values,  see 
Section  16.[ADDRESS_1027715] Name  
[CONTACT_201101], platelets, red blood cell (RBC), 
white blood cell (WBC) and differential white blood cell counts will be measured at scheduled 
visits. 
Chemistry  Serum chemistries will include glucose, urea, 
creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT, alkaline phosphatase, sodium, 
potassium, bicarbonate, calcium, phosphorus, 
total protein, albumin, and uric acid.  
Urinalysis  Dipsticks will be provided by [CONTACT_750656]. The urinalysis results for standard parameters such as protein, glucose, blood, and 
WBCs will be recorded in the appropriate eCRF.  
[COMPANY_001]  Confidential  Page 63  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Lipid Panel  A lipid profile including High Density Lipoprotein 
(HDL), Low Density Lipoprotein (LDL), total 
cholesterol, and triglycerides will be measured 
from a fasting blood sam ple. 
Cardiovascular  panel  A cardiovascular profile including lipoprotein (a), 
apolipoprotein B, apolipoprotein A -1, and 
adiponectin will be done from a blood sample.  
Pregnancy Test  Serum / Urine pregnancy test (refer to 
'Pregnancy and assessments of fert ility' section)  
8.4.4 Electrocardiogram (ECG)  
A standard 12- lead ECG will be performed as indicated in Table [ADDRESS_1027716] in the supi[INVESTIGATOR_188597] a stable baseline. The preferred sequence 
of cardiovascular data collection during study visits is ECG collection followed by [CONTACT_188651]. The Fridericia QT correction formula (QTcF) should be used for clinical 
decisions. 
Each ECG tracing should be labeled with study number, subject initials, subject number, date 
and time, and filed in the study site source documents. For any ECGs with subject safety concerns, two additional ECGs should be performed to confirm the safety finding. Clinically significant ECG findings must be discussed with the sponsor before randomization of the subject into the study. 
Clinically significant abnormalities must be recorded on the relevant section of the medical 
history/Current medical conditions/AE eCRF as appropriate.  
8.4.5 Local tolerability (Injection site reactions)  
Local tolerability at the site of i.v. injection of the study treatment will be asses sed in case of 
any local reaction, and followed up until this has disappeared.  
The assessment of pain, redness, swelling, induration, hemorrhage and itching, including severity (mild, moderate, severe) and duration, will be performed by a physician and will be recorded on the Adverse Events eCRF.  
8.4.[ADDRESS_1027717] not be given to pregnant women; therefore, effective methods of birth control must be used for women of childbearing potential (see exclusion criteria  definitions, 
Section  5.2). 
A serum β- hCG test will be performed in all women at screening. All women who are not 
surgically sterile or post -menopausal (as defined in Section  5.2) at screening will have local 
urine pregnancy tests as indicated in Table [ADDRESS_1027718] discontinue study treatment.  
8.4.7 Tolerability of secukinumab 
Tolerability will be assessed by [CONTACT_20721], laboratory values, injection site reaction  
. 

[COMPANY_001]  Confidential  Page 64  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
8.4.[ADDRESS_1027719] X -ray or MRI at screening visit 2 (except for subjects who have a valid chest  X-ray or 
MRI done within 3 months prior to screening) is performed to rule -out the presence of a 
pulmonary malignancy or infectious process, in particular, tuberculosis.  
8.4.[ADDRESS_1027720] x- ray or MRI at screening (or within 3 months prior to screening) is 
performed to rule out the presence of a pulmonary malignancy or infectious process, in particular, pulmonary tuberculosis. The radiation exposure that results from the chest X -ray 
safety measurements are estimated to be far below 1 mSv (millisievert). For effective radiation 
doses under 3 mSv (300 mrem; 300 milliroentgen equivalent man), the risk is considered to be 
minimal. Therefore, the radiation exposure in this study involves minimal risk and is necessary to ensure adequate safety measures before the treatment with a biologic.  
The safety assessments selected are standard and adequate for this indication/subject population. 

[COMPANY_001]  Confidential  Page 65  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.5 Additional assessments 
The other assessments planned for the study are:  
• Quality of Life questionnaires/ Patient reported outcomes (PROs) 
• Trial Feedback Questionnaires  
  
• HLA- B27 
• Pharmacokinetics  
  
• Activity/Mobility improvement  
• Sacroiliac Joint X -ray 
• Sacroiliac Joint MRI  

[COMPANY_001]  Confidential  Page 66  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
8.5.
2 Trial Feedback Questionnaires 
This trial will include an anonymized questionnaire, ‘Trial Feedback Questionnaire’ for 
subjects to provide feedback on their clinical trial experience. Individual subject level responses will not be reviewed by [CONTACT_431]. Responses would be used by [CONTACT_456] ([COMPANY_001]) to understand where improvements can be made in the clinical trial process. This questionnaire does not collect data about the subject's disease, symptoms, treatment effect or adverse events and therefore would not be trial data. Should any spontaneous information be collected about 
AEs, this would be reported to the investigator.  
8.5.4 HLA-B27 
A blood sample to analyze Human leukocyte antigen B27 (HLA -B27) will be obtained from all 
subjects as indicated in Table 8 -1. 
Details on the collection, handling and shipment of the sample to t he central laboratory will be 
provided to investigators in the laboratory manual  

[COMPANY_001]  Confidential  Page 67  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.5.5 Pharmacokinetics 
Pharmacokinetic (PK) samples will be collected at the visits defined in the assessment schedule 
(Table 8 -1) and Table [ADDRESS_1027721] will provide the samples’ concentration data to the team under blinded conditions. Bioanalyst will keep this information blinded until the interim clinical database lock. 
PK sample handling, labeling and shipment instructions:  
Laboratory manuals will be provided by [CONTACT_750657], sample handling and shipment. Tubes and labels will be provided by [CONTACT_37281]/sample type information 
pre-printed on the label. 
Table 8-6 PK sample log 
Week  Timepoint  PK sample number*  PK collection number  
BSL 0 h (pre -dose)  1 1 
BSL 0.5 h  2 1 
Week 4  0 h (pre -dose)  3 2 
Week 4  0.5 h  4 2 
Week 8  0 h (pre -dose)  5 3 
Week 8  0.5 6 3 
Week 16  0 h (pre -dose)  7 4 
Week 24  0 h (pre-dose)  8 5 
Week 24  0.5 h  9 5 
Week 25  anytime  10** 5 
Week 48  0 h (pre -dose)  11 6 
Week 48  0.5 h  12 6 
Week 52  anytime  13** 6 
Week 60  anytime  14** 6 
* If a PK sample is collected at an unschedule visit, the sample number will follow the pattern: 1001, 1002, etc.  
** Post -dose time point for sample number [ADDRESS_1027722] dose given at Week 48.  
PK analytical methods   
An ELISA method will be used for the bioanalytical analysis of AIN457 in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL. The detailed method description to assess the Secukinumab concentration will be described in the Bioanalytical Data Report (BDR).  
[COMPANY_001]  Confidential  Page 68  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Concentra tions below the LLOQ will be reported as “zero” and missing data will be labeled as 
such in the BDR.  

[COMPANY_001]  Confidential  Page 69  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
8.5.
7 Activity/Mobility improvement  
This study will also investigate the association between treatment with i.v. secukinumab and 
daytime activity patterns by [CONTACT_750658]'s (BASDAI,  
amongst others)  

[COMPANY_001]  Confidential  Page 70  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
8.5.8 Sacroiliac Joint X -ray 
For eligibility purpose, an SIJ X -ray will be obtained from nr- axSpA as defined in the 
assessment schedule ( Table 8 -1) and according to the imaging acquisition guidelines provided 
by [CONTACT_229705]. The X -ray images should be transferred to the central 
imaging laboratory following acquisition. The  central imaging laboratory will conduct 
independent review for all sacroiliac X -rays in this trial to determine eligibility of patients with 
nr-axSpA. 
8.5.9 Sacroiliac Joint MRI  
For eligibility purpose, an SIJ MRI will be obtained from nr- axSpA subjects as defi ned in the 
assessment schedule ( Table 8 -1) and according to the imaging acquisition guidelines provided 
by [CONTACT_229705]. The MRI images should be transferred as anonymized 
electronic files to the central imaging laboratory following acquisition. The central imaging 
laboratory will conduct independent review for all sacroiliac MR imaging in this trial.  
[ADDRESS_1027723] if, he/she believes that 
continuation would negatively impact the subject's well-being. The following circumstances require study treatment discontinuation:  
• Withdrawal of informed consent (WoC) 
• Emergence of the following adverse events: 
a. Any severe or serious adverse event that is not compatible with administration of 
study medication, including adverse events that require treatment with an unacceptable co-medication  
b. Onset of lymphoproliferative disease or any malignancy exce pt for treated basal cell 
carcinoma, treated actinic keratoses, treated in situ carcinoma of the cervix or non -
invasive malignant colon polyps which are being or have been removed 
c. Life -threatening infection 
d. Severe hypersensitivity reaction or anaphyl actic reaction  
• Any laboratory abnormalities that in the judgment of the investigator are clinically 
significant and are deemed to place the subject at a safety risk for continuation in the study (A general guidance on clinically notable laboratory values i s provided in Section  16.1 .) 
• Pregnancy 
• Use of any biologic immunomodulating agent except secukinumab 
• Any protocol deviation that results in a significant risk to the subject’s safety  
[COMPANY_001]  Confidential  Page 71  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
In addit ion to these requirements for study treatment discontinuation, the investigator should 
discontinue study treatment for a given subject if there is a lack of improvement or worsening 
of their symptoms, or if on balance, he/she thinks that continuation would be detrimental to the 
subject’s well-being. 
If discontinuation of study treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the subject’s premature discontinuation of study treatment and record this info rmation.  
Subjects who discontinue study treatment or who decide they do not wish to participate in the study further should NOT be considered withdrawn from the study UNLESS they withdraw their consent (see 'Withdrawal of Informed Consent' Section  9.1.2).  Where possible, they 
should return for the assessments indicated  in the Assessment Schedule. If they fail to return 
for these assessments for unknown reasons, every effort (e.g. telephone, e -mail, letter) should 
be made to contact [CONTACT_423]/pre -designated contact [CONTACT_49425] -up 
Section  9.1.3. This contact [CONTACT_6636].  
If the subject cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_1155], or with a person pre -designated by [CONTACT_423]. This 
telephone contact [CONTACT_6636]. 
Subjects who prematurely discontinue or withdraw during a specific treatment period should return, [ADDRESS_1027724] study treatment, for the final visit within that treatment period (i.e., 
Week 16 for treatment perio d 1 or Week 52 for  treatment period 2), as well as return for the 
follow -up visit (i.e.,Week 60) [ADDRESS_1027725] to follow -up (i.e. those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should show "due diligence" by [CONTACT_762], e.g. dates of telephone calls, registered letters, etc. 
The investigator must also contact [CONTACT_37284]’s discontinuation from study 
treatment.  
If discontinuation occu rs because treatment code has been broken, please refer to Emergency 
breaking of treatment code Section  6.6.3. 
[IP_ADDRESS] Replacement policy  
Subjects who are prematurely withdrawn from the study will not be replaced by [CONTACT_750659].  
9.1.[ADDRESS_1027726]: 
• Does not want to participate  in the study anymore, and 
• Does not allow further collection of personal data 
[COMPANY_001]  Confidential  Page 72  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.  
Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_201077] -up. 
All efforts should be made to complete the assessments prior to study withdrawal. A final evaluation at the time of the subject’s study withdrawal should be made as detailed in the assessment table.  
[COMPANY_001] will continue to keep and use collected study information (including any data resulting from the analysis of a subject’s samples until the time of withdrawal) according to applicable law. 
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may still be used for further testing/analysis in accordance with the terms of this protocol and of the informed consent form.  
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no longer be used, unless permitted by [CONTACT_1289]. They will be stored according to applicable legal requirements.  
9.1.[ADDRESS_1027727] show "due diligence" by 
[CONTACT_762], e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until his /her 
scheduled end of study visit would have been occured. 
9.1.4 Early study termination by [CONTACT_201078]. This may include reasons 
related to the benefit/ risk assessment of participating in the s tudy, practical reasons (including 
slow enrollment), or for regulatory or medical reasons. In taking the decision to terminate, [COMPANY_001] will always consider the subject welfare and safety. Should early termination be necessary, subjects must be seen as soon as possible and treated as a prematurely withdrawn subject. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subject’s interests. The investigator o r sponsor depending on the local regulation will be responsible for informing 
IRBs/IECs of the early termination of the trial.  
9.[ADDRESS_1027728] completed the study if he/she received a maximum of 52 weeks of study treatment and upon completion of the scheduled study assessments and procedures up to and including visit Week 60. 
[COMPANY_001]  Confidential  Page 73  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Information on the subject’s completion or discontinuation of the study and the reason for 
discontinuation will be recorded on the appropriate Study Phase Completion eCRF page. 
The investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing medical care. This 
medical care may inclu de initiating another treatment outside of the study as deemed 
appropriate by [CONTACT_093]. This treatment may be any non-biologic DMARD. In case of a biologic treatment, a waiting period of [ADDRESS_1027729] to the patient, if not commercially available and accessible.  
10 Safety monitoring and reporting  
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subje ct or 
clinical investigation subject after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has t he responsibility for managing the safety of individual subject and 
identifying adverse events. 
[COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of adverse events must b e sought by [CONTACT_105]- directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_109049], laboratory test findings, o r other assessments.  
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2 ):  
1. The severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. its relationship to the study treatment. If the event is due to lack of efficacy or progression of underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of 
[COMPANY_001]  Confidential  Page 74  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
underlying disease can only be evaluated m eaningfully by [CONTACT_6646], not on a 
single subject  
3. its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported  
4. whether it constitutes a SAE (see Sectio n 10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. action taken regarding with study treatment 
All adverse events must be treated appropriately. Treatment may include one or more of the following : 
• Dose not changed 
• Dose Reduced/increased  
• Drug interrupted/withdrawn  
6. its outcome  (not recovered/not resolved; recovered/resolved; recovered/resolved with 
sequelae; fatal; or unknown) 
Conditions that were already present at the time of informed consent should be recorded in medical history of the subject.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_1027730] be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and ass essment must be made at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB).  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically signifi cant 
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values  which are considered to be non- typi[INVESTIGATOR_201031]. Alert ranges for laboratory and other test abnormalities are included in Section  16.1 . 
[COMPANY_001]  Confidential  Page 75  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
10.1.2 Serious adverse events (SAEs) 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_108999]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g. defined as an event that jeopardizes the subject or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_331979]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_6536]  (please refer to the ICH -
E2D Guidelines). 
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease pr ogression of the 
study indication. 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse event irrespective if a clinical event has occurred.  
[COMPANY_001]  Confidential  Page 76  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
10.1.[ADDRESS_1027731] be re ported separately as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must a ssess the relationship of each SAE to study treatment , 
complete the SAE Report Form in English, and submit the completed form within 24 hours to [COMPANY_001]. Detailed instructions regarding the submission process and requirements on investigator's signature [CONTACT_750679] h site.  
If the SAE is previously not documented in the Investigator’s Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a CMO & PS Department associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been 
reported. 
Suspected Unexpected Serious Adverse Reactio ns (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_1027732] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_750660] t Safety (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment any pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
[COMPANY_001]  Confidential  Page 77  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse/Abuse  Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.[ADDRESS_1027733] safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study (irrespective of whether classified/reported as AE/SAE):  
• Liver laboratory triggers, which will require repeated assessments of the abnormal laboratory parameter  
• Liver events, which will require close observation, follow -up monitoring and contributing 
factors are recorded on the appropriate CRFs 
Please refer to Table 16-1 in Section  16.6 for complete definitions of liver laboratory triggers 
and liver events. 
Every liver event defined in Table 16-1 should be followed up by [CONTACT_750661], as summarized below. Additional details on actions required in case 
[COMPANY_001]  Confidential  Page 78  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
of liver events are outlined in Table 16 -2. Repeat liver chemistry tests (i.e. ALT,  AST, TBL, 
PT/INR, ALP and G- GT) to confirm elevation.  
• These liver chemistry repeats will be performed using the central laboratory. If results will 
not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the subject. If a liver event is subsequently 
reported, any local liver chemistry tests previously conducted that are associated with this event should have results recorded on the appropriate CRF.   
• If the initial elevation is confirmed, close observation of the subject will be initiated, including consideration of treatment interruption if deemed appropriate.  
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment Section  9.1.1), if appropriate  
• Hospi[INVESTIGATOR_131539]  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event should include  
• Investigations which can be based on investigator’s discretion: serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, ex clusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
10.2.[ADDRESS_1027734] of blocking IL -17A on the kidney. All subjects with laboratory tests resulting in 
clinically significant abnormal values (see Se ction  16.1 for notable laboratory values) are to be 
followed until the values return to normal ranges or until a valid reason, other than treatment related AE, is defined. Standard renal function tests (blood urea nitroge n, serum creatinine) will 
be obtained at regular intervals, but special measures for renal safety monitoring are not planned. 
11 Data Collection and Database management  
11.1 Data collection  
Designated investigator staff will enter the data required by [CONTACT_644741] (eCRF). The eCRFs have been built using fully validated secure web-enabled software that conforms to [ADDRESS_1027735] been  trained. Automatic validation programs 
check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649].  
[COMPANY_001]  Confidential  Page 79  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate  
After final database lock, the investigator will receive copi[INVESTIGATOR_109002].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.  
11.2 Database management and quality control  
[COMPANY_001] personnel (or designated C RO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigati onal site via the EDC system. Designated investigator site staff are required to 
respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments and prior medications entered into the database will be coded using the 
World  Health Organization (WHO) Drug Reference List, which employs the Anatomical 
Therapeutic Chemical classification system. Medical history/current medical conditions and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Randomization codes and data about all study treatment (s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of [COMPANY_001].  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis/moved to restricted area to be accessed by[CONTACT_49433]. Any changes to the database after that time can only be made after written agreement by [CONTACT_188660]. 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and data capture requirements (i.e., eCRFs) with the investigators and their staff. During the study, [COMPANY_001] employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will 
visit the site to check the completeness of subject records, the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, th e progress of enrollment, 
and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.  
[COMPANY_001]  Confidential  Page 80  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
The investigator must maintain so urce documents for each subject in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. Al l information on CRFs must be traceable to these source documents in the 
subject’s file.  The investigator must also keep the original informed consent form signed by [CONTACT_423] (a signed copy is given to the subject). 
The investigator must give the monit or access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
subjects will be disclosed. 
[ADDRESS_1027736] data at the time 
the study ends. Any data analysis carried out independently by [CONTACT_30817]. 
Summary statistics for continuo us variables will generally include the number of subjects (N), 
minimum, lower quartile, mean, standard deviation (SD), median, upper quartile, and 
maximum. For categorical or binary variables, the number and percent of subjects in each category will be presented. P- values presented will be two -sided unless otherwise specified.  
Inferential efficacy comparisons with placebo will be performed on the first 16 weeks of treatment.  
Data analyses will be presented by [CONTACT_1570]. Efficacy and safety data for the 16- week 
placebo -controlled period and the entire treatment period as appropriate will be presented by 
[CONTACT_750662]. Subjects may be included in more than one treatment group for some analyses (e.g., exposure adjusted adverse events over the entire treatment period).  
These treatment groups represent the regimens to which subjects will be eligible to be randomized: 
• Secukinumab i.v. regimen 
• Placebo regimen  
Note that the treatment groups above for a subject may differ depending on the time period of 
the analysis and whether one assesses the subject for efficacy or safety (see Section  12.1 for 
details).   
12.1 Analysis sets  
The following analysis sets will be used in this study: 
[COMPANY_001]  Confidential  Page 81  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Randomized set:  The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis -randomized subjects (mis- randomized in IRT) will be exclu ded 
from the randomized set.  
Mis- randomized subjects are defined as those subjects who were mistakenly randomized into 
the IRT prior to the site confirming all eligibility criteria had been met and to whom no study 
medication was given. Mis -randomized subj ects are treated as screen failures.  
Full analysis set (FAS) : The FAS will be comprised of all subjects from the randomized set to 
whom study treatment has been assigned. Following the intent -to-treat principle, subjects will 
be evaluated according to the treatment assigned to at randomization.  
Safety set : The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be evaluated according to treatment received. 
12.[ADDRESS_1027737] demographics and other baseline characteristics  
Demographics and baseline characteristics 
The following common background and demographic variables will be summarized: 
• Gender, age, race, ethnicity, weight, height, and BMI. 
Baseline disease characteristics will also be summarized for the following variables:  
• Patient’s global assessment of disease activity and other ASAS components, hsCRP (mg/L 
and >ULN), , prior use (yes/no) of TNF -alpha inhibitors, use (yes/no) and 
separate dose of MTX (mg/week), sulfasalazine (g/day) an d systemic corticosteroids 
(mg/day) at randomization, time since first diagnosis of axSpA (years), modified [LOCATION_001] criteria for AS, HLA -B27, , total back pain (VAS), nocturnal back pain (VAS), total 
BASDAI score, spi[INVESTIGATOR_18172] (BASDAI question #2)  
. 
Medical history 
A history of axSpA with focus on previous extra -articular involvement and past therapi[INVESTIGATOR_750614]. Any other significant prior or 
active medical condition at the time of signing informed consent will be recorded and coded using the MedDRA dictionary. These medical conditions will be summarized by [CONTACT_168322].  
To establish a baseline level of cardiovascular risk, the number and percentage of subjects with pre-solicited cardiovascular risk factors will be summarized by [CONTACT_1570]. The number 
of cardiovascular risk factors that each subject has will also be summarized by [CONTACT_1570]. If it is unknown whether or not a subject currently or previously experienced a specific cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not occur for that subject.  

[COMPANY_001]  Confidential  Page 82  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
12.3 Treatments  
Study treatment  
The analysis of study treatment data will be base d on the safety set. The number of visits with 
active and placebo i.v. infusions received will be presented by [CONTACT_1570]. 
The duration of exposure to study treatment will also be summarized by [CONTACT_1570]. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g., any exposure, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented.  
Prior and concomitant medication 
Prior and concomitant medications will be summarized in separate tables by [CONTACT_1570].  
Prior me dications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized study 
treatment and the date of the last study visit will be a concomitant medication, including those which were started pre -baseline and continued into the period where study treatment is 
administered.  
Medications will be presented in alphabetical order, by [CONTACT_121974] (ATC) codes and grouped by [CONTACT_121975]. Tables will show the overall number and percentage of subjects receiving at least one treatment of a particular ATC code and at least one treatment in a particular anatomical main group.  
Significant prior and concomitant non-drug therapi[INVESTIGATOR_471715].  
Prior surgeries and procedures are defined as surgeries and procedures done prior to first dose of study treatment. Any surgeries and procedures done between the day of first dose of study treatment and within the date of the last study visit will be a concomitant surgeries and procedures, including those which were started pre -baseline and continued into the period 
where study treatment is administered.  
The number and percentage of subjects receiving prior and concomitant axSpA therapy will be 
presented by [CONTACT_250364][INVESTIGATOR_144930] (primary lack of efficacy, secondary lack of efficacy, lack of tolerability , other) and the total 
duration of exposure to axSpA therapi[INVESTIGATOR_144931].  
12.4 Analysis of the primary endpoint(s)  
Details of the testing strategy including primary and secondary endpoints are provided in Section  12.5.1. 
12.4.1 Definition of primary endpoint(s)  
The primary efficacy variable is response to treatment according to the ASAS40 criteria at Week 16 in patients with active axSpA (AS and nr -axSpA). The analysis of the primary variable 
will be based on the FAS population. 

[COMPANY_001]  Confidential  Page 83  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
12.4.2 Statistical model, hypothesis, and method of analysis 
The estimand for primary endpoint is defined as follows: 
A. Population: defined thr ough appropriate inclusion/exclusion criteria to reflect the targeted 
axSpA population (AS and nr- axSpA)  
B. Variable: composite of remaining on the study and on randomized treatment through 16 
weeks and achieving ASAS40 response at 16 weeks 
C. Intercurrent event: the intercurrent event is captured through the variable definition D. Population- level summary: difference in proportions of responders between the 
secukinumab and placebo arms The statistical hypothesis for ASAS40 being tested is that there is no difference in the proportion 
of subjects fulfilling the ASAS40 criteria at Week 16 in the secukinumab i.v. regimen versus placebo regimen.  
Let p
0 denote the proportion of ASAS40 responders at Week 16 for placebo regimen and p 1 
denote the proportion of ASAS40 responders at Week 16 for secukinumab i.v. regimen. 
In statistical terms, H 1: p1= p 0, HA1: p1≠ p 0, i.e., 
H1: secukinumab i.v. regimen is not different to placebo regimen with respect to ASAS40 
response at Week 16  
The primary analysis will be conducted via logistic regression with treatment and stratification 
factor (disease condition) as factors and weight as a covariate. Difference in marginal response proportions with p- value and 95% confidence interval (CI) will be presented comparing 
secukinumab i.v. regimen to placebo.  
12.4.3 Handling of missing values/censoring/discontinuations 
Missing data for ASAS40 response and other binary efficacy variables (e.g., ASAS  5/6, etc.) 
for data up to Week 16 will be handled as follows: 
1. Patients who drop out of the trial for  any reason will be considered as non -responders 
from the time they drop out through Week [ADDRESS_1027738] the required data to compute responses (e.g., ASAS 
components) at baseline and at the specific timepoint will be classified as non-responders 
at the specific timepoint.  
Patients who are unblinded prior to the scheduled time point will be considered non -responders 
from the time of unblinding up to Week 16. The primary analysis will use the non-responder imputation. 
Continuous variables (e.g., ASAS components) will be analyzed using a mixed- effects model 
repeated measures (MMRM) which is valid under the missing at random (MAR) assumption. 
As such, single -point imputation of missing data will not be performed (e.g., LOCF). For 
analyses of these parameters, if all post -baseline values are missing then these missing values 
will not be imputed and this patient will be removed from the analysis of the corresponding variable, i.e., it might be that the number of patients providing data to a n analysis is smaller 
than the number of patients in the FAS. 
[COMPANY_001]  Confidential  Page 84  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
  
12.4.[ADDRESS_1027739]. These analyses will center on the deviations in model assumptions and the treatment of missing data. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ASAS40 response at Week 16 will also be evaluated using a non- parametric 
ANCOVA model ( Koch  et al 1998 ) with the same independent variables as the logistic 
regression model. In addition, further logistic regression models may be conducted which explore the impact of other baseline or disease characteristics (and respective interactions with treatment group) on response. 
The impact of missing data on the analysis results of ASAS40 will be assessed as well by 
[CONTACT_750663]. 
These may include, but are not limited to: 
• Multiple imputation  
• Observed data analysis 
• Tippi[INVESTIGATOR_18275] 
12.5 Analysis of secondary endpoints  
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
The secondary e fficacy variables and the method for adjusting for multiplicity are described 
below. Secondary efficacy variables will be analyzed using the FAS population. Handling of 
missing data for secondary variables included in the testing strategy will be the same as for the primary variable.  
Estimand definition for the secondary variables 
Estimand definition for the secondary binomial variables (e.g., ASAS  5/6, etc.) is the following:  
A. Population: defined through appropriate inclusion/exclusion criteria to reflec t the targeted 
axSpA population 
B. Variable: composite of remaining on the study and on randomized treatment through 16 
weeks and achieving variable response at 16 weeks 
C. Intercurrent event: the intercurrent event is captured through the variable definit ion 
D. Population- level summary: difference in proportions of responders between the treatment 
conditions The estimand of binary variables is (secukinumab vs placebo) obtained from a logistic 
regression model at week 16 in the FAS population. In the analysis, patients droppi[INVESTIGATOR_750615] 16 or having missing response data at week 16 are considered as 
non-responders.  
[COMPANY_001]  Confidential  Page 85  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Estimand definition for the secondary continuous variables (e.g., BASDAI, etc.) is the 
following:  
A. Population: define d through appropriate inclusion/exclusion criteria to reflect the targeted 
axSpA population 
B. Variable: change from baseline in the variable of interest  
C. Intercurrent event: had no intercurrent events occured before week 16 D. Population- level summary: difference in variable means between the treatment conditions  
The estimand of continuous variables at week 16 is (secukinumab vs placebo) obtained from 
MMRM in the FAS population assuming patients droppi[INVESTIGATOR_750616] 16 are missing -at-random. MAR imputation will be implemented through an MMRM or 
multiple imputation model.  
ASDAS- CRP major improvement at Week 16 
Response at Week 16 to ASDAS -CRP major improvement criteria will be evaluated using a 
logistic regression model with treatment, stratification factor (disease condition) as factors and weight and baseline score as a covariate.  
BASDAI at Week 16 
Between -treatment differences in the change from baseline in BASDAI will be evaluated using 
MMRM with treatment group, stratification fa ctor (disease condition) and analysis visit as 
factors and baseline BASDAI score and weight as continuous covariates. Treatment by [CONTACT_750664]. An unstructure d covariance structure will be assumed for the model.  
ASAS  5/6 at Week 16 
The proportion of patients meeting the response criteria will be evaluated using a logistic 
regression model with treatment group, stratification factor (disease condition) as factors and 
weight as a covariate.  
BASFI at Week 16 
Between -treatment differences in the change from baseline in BASFI will be evaluated using 
MMRM with treatment group, stratification factor (disease condition) and analysis visit as 
factors and baseline BASFI score and weight as continuous covariates. Treatment by [CONTACT_750665]. An unstructured covariance structure will be assumed for the model. 
SF-36 PCS at Week 16 
See Section  12.5.7 Patient Reported Outcomes.  
[COMPANY_001]  Confidential  Page 86  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
ASQoL at Week 16 
Summary statistics of observed data by [CONTACT_750666]. Between -treatment differences will be evaluated usin g 
MMRM. Treatment group, stratification factor (disease condition) and analysis visit will be included as categorical factors and baseline ASQoL scores and weight as continuous covariates. Treatment by [CONTACT_750667] v isit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the model. 
hsCRP at Week [ADDRESS_1027740] that the data are not 
normally distributed ( Huffman  et al 2006), analysis will be performed on the log
e ratio of the 
treatment value vs baseline value (calculated by [CONTACT_319690] -baseline value by [CONTACT_750668] e transformation) to normalize the distribution of hsCRP at each 
analysis visit. Between -treatment differences in the change in hsCRP relative to baseline will 
be evaluated using MMRM with treatment group, stratification factor (disease condition) and analysis visit as factors and log
e baseline hsCRP and weight as continuous covariates. 
Treatment by [CONTACT_750669] e baseline hsCRP by [CONTACT_750670]. An unstructured covariance structure will be assumed for the model. The estimate and the 2 -sided 95% confidence intervals obtained from the model will be 
back transformed to the original scale.  
ASAS20 at Week 16 
The proportion of patients meeting the response criteria will be evaluated  using a logistic 
regression model with treatment group, stratification factor (disease condition) as factors and 
weight as a covariate.  
ASDAS- CRP inactive disease at Week 16 
Response at Week 16 to ASDAS -CRP inactive disease criteria will be evaluated usin g a logistic 
regression model with treatment, stratification factor (disease condition) as factors and weight 
and baseline score as a covariate.  
ASAS partial remission at Week 16 
Response at Week 16 to ASAS partial remission criteria will be evaluated usin g a logistic 
regression model with treatment, stratification factor (disease condition) as factors and weight 
as a covariate.  
PSQI at Week 16  
Summary statistics of observed data by [CONTACT_750671] h treatment regimen. Between -treatment differences will be evaluated using 
MMRM. Treatment group, stratification factor (disease condition) and analysis visit will be included as categorical factors and baseline PSQI scores and weight as continuous covaria tes. 
Treatment by [CONTACT_750672] 87  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. 
Testing Strategy 
The following null hypotheses will be included in the testing strategy, and type -I-error will be 
set such that a family -wise type-I- error of 5% is kept:  
Primary objective:  
H1: secukinumab i.v. regimen is not different to placebo regimen with respect to signs and 
symptoms (ASAS40 response) in axSpA patients at Week 16  
Secondary objectives: 
H2: secukinumab i.v. regimen is not different to placebo regimen with respect to ASDAS -CRP 
major improvement in axSpA patients at Week 16  
H3: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in total BASDAI in axSpA patients at Week 16  
H4: secukinumab i.v. regimen is not different to placebo regimen with respect to ASAS  5/6 
response in axSpA patients at Week 16  
H5: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in BASFI in axSpA patients at Week 16  
H6: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in SF -36 PCS in axSpA patients at Week 16 
H7: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in ASQoL in axSpA patients at Week 16  
H8: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in hsCRP in axSpA patients at Week 16  
H9: secukinumab i.v. regimen is not different to placebo regimen with respect to ASAS20 
response in axSpA patients at Week 16  
H10: secukinumab i.v. regimen is not different to placebo regimen with respect to ASDAS -CRP 
inactive disease in axSpA patients at Week  16 
H11: secukinumab i.v. regimen is not different to placebo regimen with respect to ASAS partial 
remission in axSpA patients at Week 16  
H12: secukinumab i.v. regimen is not different to placebo regimen with respect to change from 
baseline in PSQI in axSpA patients at Week 16  
[COMPANY_001]  Confidential  Page 88  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Figure 12-1 Testing strategy 
 
The family -wise error will be set to α=5% and it will be controlled with the proposed sequential 
testing strategy as described in Figure 12-1. The primary hypothesis (H 1) for the primary 
objective (ASAS40 at Week 16) for secukinumab i.v. regimen versus placebo will be tested at 
α-level. If the hypothesis H 1 is rejected then the whole α will be passed to the next hypothesis 
(H2) which will be tested at α -level. This procedure will continue (pending rejection of the null 
hypotheses) until H 12 is rejected.  
Of note, in the description above, rejection of a hypothe sis refers to rejection of the two -sided 
hypothesis; however the level of a rejected hypothesis is only passed on according to the sequence for the test of another hypothesis if the treatment effect is in favor of secukinumab.  
12.5.2 Safety endpoints 
Adverse events  
Treatment -emergent adverse events (i.e., events started after the first dose of study treatment or 
events present prior to the first dose of study treatment but increased in severity based on preferred term and on or before last dose + 84 days) will be summarized.  
Adverse events will be summarized by [CONTACT_1601], for each treatment group, the number and percentage of subjects having any AE, having an AE in each primary system organ class and having each individual AE (preferred term). Summaries will also be presented for AEs by [CONTACT_201092]. If a subject reported more than one adverse event with the same preferred term, the adverse event with the greatest severity will be presented. If a subject reported more than one adverse event within the same primary system organ class, the subject will be counted only once with the greatest severity at the system organ class level, where applicable. Serious adverse events will also be summarized.  
As appropriate, the incidence of AEs wil l be presented per [ADDRESS_1027741] years of exposure 
(exposure- adjusted incidence rates).  
Separate summaries will be provided for death, serious adverse event, other significant adverse events leading to discontinuation and adverse events leading to dose adjus tment (including 
study treatment discontinuation). 
A graphical display of relative frequencies within system organ classes and relative risks, as 
appropriate, will be presented. 
[COMPANY_001]  Confidential  Page 89  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
When adjudication is required of major cardiovascular events, a summary of those types of 
events as reported by [CONTACT_250368]. 
Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology and serum chemistry). Descriptive summary statistics for the change from baseline to each study visit will be presented. These descriptive summaries will be presented by [CONTACT_109057], laboratory test and treatment group. Change from baseline will only be summarized for subjects with both baseline and post baseline. 
For each parameter, the maximum change from baseline within each study period will be 
evaluated analogously. 
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative  to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was normal, low, or high for each visit value relative to whether or not the baseline value was normal, l ow, 
or high. These summaries will be presented by [CONTACT_109058]. Shifts will be presented by [CONTACT_250369] -baseline.  
 
 
Vital signs  
Analysis of t he vital sign measurements using summary statistics for the change from baseline 
for each post -baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only be summarized f or subjects 
with both baseline and post- baseline values.  
12.5.3 Pharmacokinetics 
All subjects with concentration data will be included in the PK data analysis.  
Pharmacokinetic variables 
The following PK parameter will be determined: Cmin,ss. Cmin,ss will be determined using 
Phoenix software. Individual serum concentrations in µg/mL will be listed. All concentrations below the limit of quantification or missing data will be labeled as such in the concentration data listings. Concentrations below the limit of quantification will be treated as zero in summary statistics for concentration data only.  
During modeling of the PK of secukinumab, the broad principles outlined in the FDA Guidance for Industry: Population Pharmacokinetics  will be followed.  

[COMPANY_001]  Confidential  Page 90  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Statistical methods for pharmacokinetic analyses  
Summary statistics by [CONTACT_765]/time will be provided for the above mentioned parameter and will 
include arithmetic and geometric means, SD, median, minimum and maximum. Individual concentrations will be listed by [CONTACT_1130]. 
12.5.7 Patient Reported O utcomes (PROs)  
Patient reported outcomes will be ev aluated based on FAS unless otherwise specified.  
BASDAI  
The following variables will be evaluated:  
• BASDAI  
  
For BASDAI, see Section  12.5.1 Efficacy and/or Pharmacodynamic endpoint(s ) for details.  

[COMPANY_001]  Confidential  Page 91  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
 
 
BA
SFI 
See Section  12.5.1 Efficacy and/or Pharmacodynamic endpoint(s). 
 
 
Patient’s assessment of back pain intensity (VAS)  
Summary statistics of observed data by [CONTACT_750673]’s assessment 
of back pain intensity will be provided for each treatment. 
SF-36 
The following variables will be evaluated:  
• SF- 36 domain scores (based on a scale of 0 -100) 
• SF-36 PCS  (norm- based scores)  
• SF- 36 PCS  (improvement of ≥ 2.5 points, Lubeck 2004) 
For the change in SF- 36 summary scores (PCS ), summary statistics will be provided 
using observed data for each treatment regimen.  
For the responder analyses, the proportion of responders will be descriptively summarized along 
with its 95% CI for each randomized treatment based on observed data. 
The SF- 36 domain scores will be summarized by [CONTACT_3148].  
ASQoL  
See Section  12.5.1 Efficacy and/or Pharma codynamic endpoint(s).  

[COMPANY_001]  Confidential  Page 92  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
PSQI  
S
ee Section  12.5.1 Efficacy and/or Pharmacodynamic endpoint(s). 

[COMPANY_001]  Confidential  Page 93  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
The
 secukinumab i.v. regimen will be compared for primary and secondary variables as part of 
the regular statistical models (e.g., logistic regression  and MMRM).  
For binary variables, the proportion of responders for these endpoints (e.g., achieving ASAS20) 
may be summarized along with its 95% CI for each randomized treatment based on observed data. Details will be provided in the statistical analysis plan.  
Between -treatment comparisons for binary variables in the FAS population (e.g., ASAS20, 
ASAS40, ASDAS inactive disease, etc.) at individual analysis visits will be evaluated in a logistic regression model with treatment group, stratification  factor (disease condition) as 
factors and baseline score (if appropriate) and weight as covariates. Difference in marginal 

[COMPANY_001]  Confidential  Page 94  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
response proportions with p- value and 95% CI will be presented for treatment comparison up 
to Week 16. 
For continuous variables, sum mary statistics may be provided for the variables using the 
observed data or change from baseline for each treatment regimen. Summary statistics include 
N, mean, SD, minimum, lower quartile, median, upper quartile and maximum. Details will be provided in t he statistical analysis plan.  
Continuous variables (e.g., change from baseline in ASDAS) will be evaluated using MMRM with treatment regimen, stratification factor (disease condition) and analysis visit as factors and weight and baseline score as continuous covariates. Treatment by [CONTACT_750674]. An unstructured covariance structure will be assumed for this model. Variables such as hsCRP whose distribution is not anticipated to be normal will be transformed and analyzed on the log
e scale and back 
transformed prior to presentation.  
12.7 Interim analyses  
The primary endpoint analysis will be performed after all subjects complete Week 16 in order 
to support regulatory filing. As the primary analysis is scheduled at Week 16, no adjustment 
will be made to the testing strategy to control family -wise type I error rate for this analysis.  

[COMPANY_001]  Confidential  Page 95  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
12.8 Sample size calculation  
12.8.1 Primary endpoint(s)  
An overall type I error (2 -sided) of 5% will be used to control type I error. Secukinumab i.v. 
regimen will be tested versus placebo with respect to the primary endpoint (ASAS40 response 
at Week 16). A sample size of 250 axSpA patients (200 AS patients and 50 nr -axSpA patients) 
per group is deemed appropriate to achieve adequate power for the primary and secondary endpoints for this study.  
An ASAS40 response rate of about 28.2% for the AS population in the placebo group at week 16 was reported in a published phase III study (CAIN457F2320). The ASAS40 response to secukinumab 150 mg is estimated to be 44.9% in the AS population based on the lower bound of the 90% confidence interval of risk difference from the meta -analysis of 3 phase III studies 
(CAIN457F2310, CAIN457F2320 and CAIN457F2308). With 250 patients per treatment group (200 AS patients and 50 nr -axSpA patients), there would be approximately 96% power to detect 
a treatment difference of 16.7% in ASAS40 response rates between secukinumab and placebo in the evaluation of the primary efficacy hypothesis at Week 16 (Chi Square test, NQuery 7.0). The overall sample size will be 500 patients (400 AS patients and 100 nr -axSpA patients) for a 
randomization ratio of 1:1. 
12.8.2 Secondary endpoint(s)  
The estimated power with the chosen sample size for secondary efficacy endpoints based on 
the pooled results of the same phase III studies (CAIN457F2310, CAIN457F2320 and CAIN457F2308) are summarized in Table 12 -1 for binary endpoints and Table 12-2 for 
continuous endpoints.  
Table 12-1 Summary of power for binary secondary endpoints 
Endpoint  Response Rate  Power  
  Secukinumab(N = 200 
AS + 50 nr -axSpA)  Placebo (N = 200 AS + 
50 nr -axSpA)    
ASAS  5/6 44.2%  19.5%  99% 
ASDAS- CRP major 
improvement  27.8%  6.4%  99% 
ASAS20  59.0%  38.4%  99% 
ASDAS- CRP inactive 
disease  13.6%  3.5%  97% 
ASAS partial remission  15.2%  5.5%  92% 
Table 12-[ADDRESS_1027742] 
deviation  Power  
  Secukinumab(N = 
200 AS + 50 nr -
axSpA)  Placebo (N = 200 
AS + 50 nr -
axSpA)    
hsCRP1 -0.79 0.09 0.867  99% 
BASDAI  -2.61 -1.48 2.241  99% 
BASFI  -2.14 -1.13 2.253  99% 
[COMPANY_001]  Confidential  Page 96  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
SF-36 PCS  6.87 3.99 6.898  99% 
ASQoL  -4.46 -2.56 4.714  99% 
PSQI2 -1 0 3.9 81% 
1 hsCRP is in log scale  
2 Source: mean change from baseline is from Karatas  et al 2018 (AS study, median was used) and 
common standard deviation is from Taylor -Gjevre  et al 2011 (RA study, largest standard deviation was 
used).  
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the International Conference on Harmonisation (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki.  
13.2 Responsibilities of the investigator and IRB/IEC  
Before in itiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, subject recruitmen t procedures (e.g. 
advertisements) and any other written information to be provided to subjects. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these  documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regul atory authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately that this 
request has been made.  
13.[ADDRESS_1027743]. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT 
etc.) .  
For details on the [COMPANY_001] publication policy including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator meetings.  
[COMPANY_001]  Confidential  Page 97  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
13.[ADDRESS_1027744] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducte d to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
[ADDRESS_1027745] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and Health Authorities, where required, it cannot be implemented.  
14.[ADDRESS_1027746] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to impleme ntation. 
Only amendments that are required for subject safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of for mal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any subject included in this study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page 98  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
[ADDRESS_1027747]  
Baraliakos X, Braun J (2011) Spondyloarthritides. Best Pract Res Clin Rheumatol; 25(6): 
825-42. 
Baraliakos X, Braun J (2015) Non- radiographic axial spondyloarthritis and ankylosing 
spondylitis: what are the similarities and differences? RMD Open; 1(suppl 1): e000053. 
Baraliakos X, Landewé R, Hermann KG, et al (2005) Inflammation in ankylosing spondyli tis: 
a systematic description of the extent and frequency of acute spi[INVESTIGATOR_750617]. Ann. Rheum. Dis ; 64(5):730 -4.  
Baraliakos X, Listing J, Fritz C, et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years --early clinical response predicts long -term 
outcome. Rheumatology (Oxford); 50(9):1690-9. 
Batmaz İ, Sarıyıldız MA, Dilek B, et al (2013) Sleep quality and associated factors in 
ankylosing spondylitis: rela tionship with disease parameters, psychological status and quality 
of life. Rheumatol. Int; 33(4):1039 -45. 
 
Braun J, Brandt J, Listing J, et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet p; 359(9313):1187-93.  
Cella DF, Tulsky DS, Gray G, et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol; 11(3):570- 9. 
Dougados M, Simon P, Braun J, et al (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epi[INVESTIGATOR_18284]. Ann. Rheum. Dis; 70(2):249- 51. 
EMA 2017 Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis. 
FDA Guidance for Industry:  Population Pharmacokinetics. 
https://www.fda.gov/media/[ZIP_CODE]/download. Gladman  DD (2007) Axial disease in psoriatic arthritis. Curr Rheumatol Rep; 9(6):455-60. 
Heuft -Dorenbosch L, Spoorenberg A, van Tubergen A, et al (2003) Assessment of enthesitis 
in ankylosing spondylitis. Ann. Rheum. Dis; 62(2):127-32. Huffman KM, Samsa GP, Slent z CA, et al (2006) Response of high- sensitivity C -reactive 
protein to exercise training in an at -risk population. Am. Heart J; 152(4):793-800.  
Karatas G, Bal A, Yuceege M, et al (2018) Evaluation of sleep quality in patients with 
ankylosing spondylitis and efficacy of anti -TNF -α therapy on sleep problems: A 
polisomnographic study. Int J Rheum Dis; 21(6):1263-1269. 

[COMPANY_001]  Confidential  Page 99  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Koch GG, Tangen CM, Jung JW, et al (1998) Issues for covariance analysis of dichotomous 
and ordered categorical data from randomized clinical trials and non- parametric strategies for 
addressing them. Stat Med; 17(15-16):1863-92.  
Leverment S, Clarke E, Wadeley A, et al (2017) Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non- radiographic axial 
spondyloarthritis: a systematic review. Rheumatol. Int; 37(2):257-271. 
Lubeck DP (2004) Patient- reported outcomes and their role in the assessment of rheumatoid 
arthritis. Pharmacoeconomics; 22([ADDRESS_1027748] 1):27- 38. 
Lukas C, Landewé R, Sieper J, et al (2009) Development of an ASAS- endorsed disease 
activity score (ASDAS) in patients with ankylosing spondylitis. Ann. Rheum. Dis;  68(1):18-
24. 
Machado PM, Landewé RB, van der Heijde DM (2011) Endorsement of definitions of disease 
activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J. Rheumatol;  38(7):1502-6.  
McH
orney CA, Ware JE, Raczek AE (1993) The MOS 36 -Item Short -Form Health Survey 
(SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care; 31(3):247-63. 
Rudwaleit M, Feldtkeller E, Sieper J (2006) Easy assessment of axial spondyloarthritis (early 
ankylosing spondylitis) at the bedside. Ann. Rheum. Dis; 65(9):1251-2.  
Rudwaleit M, van der Heijde D, Landewé R, et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis;  68(6):777-83.  
Said-Nahal R, Miceli -Richard C, Berthelot JM, et al (2000) The familial form of 
spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. Arthritis Rheum; 43(6):1356-65. 
Sieper J, Rudwaleit M, Baraliakos X, et al (2009) The Assessment of SpondyloArthritis 
international Society (ASAS ) handbook: a guide to assess spondyloarthritis. Ann. Rheum. 
Dis; [ADDRESS_1027749] 2:1-44.  
Sieper J, van der Heijde D (2013) Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum; 65(3):543-51.  
Song IH, Weiß A, Hermann KG, et al (2013) Similar response rates in patients with ankylosing spondylitis and non- radiographic axial spondyloarthritis after 1 year of treatment 
with etanercept: results from the ESTHER trial. Ann. Rheum. Dis; 72(6):823-5. 
Taylor- Gjevre RM, Gjevre JA , Nair BV, et al (2011) Improved Sleep Efficiency after Anti-
Tumor Necrosis Factor α Therapy in Rheumatoid Arthritis Patients. Ther Adv Musculoskelet 
Dis; 3(5):227-33. 

[COMPANY_001]  Confidential  Page 100  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Wallis D, Haroon N, Ayearst R, et al (2013) Ankylosing spondylitis and nonradiographic 
axial spondyloarthritis: part of a common spectrum or distinct diseases? J. Rheumatol; 40(12):2038-41. 
Ware JE, Sherbourne CD (1992) The MOS 36- item short -form health su rvey (SF-36). I. 
Conceptual framework and item selection. Med Care; 30(6):473-83. 
Yellen SB, Cella DF, Webster K, et al (1997) Measuring fatigue and other anemia- related 
symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J 
Pain Symptom Manage; 13(2):63- 74. 
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the [LOCATION_001] criteria. Arthritis Rheum; 27(4):361-8.  
 
[COMPANY_001]  Confidential  Page 101  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
16 Appendices  
16.1 Appendix 1: Clin ically notable laboratory values and vital signs  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests.  
Clinically notable values will be forwarded to [COMPANY_001] at the same time that they are sent to  
investigators. Any action based on these laboratory values should be discussed with [COMPANY_001] personnel.  
Table 16-1 Safety Analyses: Expanded Limits and Notable Criteria  
    Notable Criteria  
Laboratory Variable    Standard Units  SI Units  
LIVER FUNCTION AND RELATED VARIABLES  
SGOT (AST)    >[ADDRESS_1027750]  >[ADDRESS_1027751]  
SGPT (ALT)    >[ADDRESS_1027752]  >[ADDRESS_1027753]  
Bilirubin    >[ADDRESS_1027754]  >[ADDRESS_1027755]  
Alkaline phosphatase    >2.[ADDRESS_1027756]  >2.[ADDRESS_1027757]  
        
RENAL FUNCTION, METABOLIC AND ELECTROLYTE VARIABLES  
Creatinine (serum)    >[ADDRESS_1027758]  >[ADDRESS_1027759]  
HEMATOLOGY VARIABLES  
Hemoglobin: 20 g/L decrease from baseline  
Platelet count: <100x10E9/L 
White blood cell count: <0.[ADDRESS_1027760] Neutrophils: <0.[ADDRESS_1027761] 
[COMPANY_001]  Confidential  Page 102  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
16.2 Appendix 2: Modified [LOCATION_001] criteria  
Clinical criteria:  
· Low back pain and stiffness for more than [ADDRESS_1027762].  
· Limitation of motion of the lumbar spi[INVESTIGATOR_750618].  
· Limita tion of chest expansion relative to normal values correlated for age and sex. 
Radiological criterion  
· Sacroiliitis grade ≥2 bilaterally or grade 3–[ADDRESS_1027763] one clinical criterion . 
16.3 Appendix 3: ASAS, BASFI  
The ASAS  response measures consist of the following assessment domains ( Sieper  et al 2009).  
Main ASAS domains:  
1. Patient’s global assessment of disease activity measured on a VAS scale 
2. Patient’s assessment of back pain, represented by [CONTACT_90202], 
both measured on a VAS scale 
3. Function represented by [CONTACT_90203] [ADDRESS_1027764] 2 questions on the 6-question BASDAI as measured by [CONTACT_750652]:  
 
2. C reactive protein (acute phase reactant)Bath Ankylosing Spondylitis Functional Index (BASFI) 
The BASFI is a set of [ADDRESS_1027765] 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects’ ability to cope with everyday life. A 10cm visual analog scale is used to answer the questions. The mean of the ten scales gives the BASFI score – a value between 0 
and 10.  

[COMPANY_001]  Confidential  Page 103  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
.B
ath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)  
The BASDAI consists of a zero through 10 scale ([ADDRESS_1027766] 
problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS: 
1. How would you describe the overall level of fatigue/tiredness you have experienced? 
2. How would you describe the overall level of AS neck, back or hip pain you have had? 

[COMPANY_001]  Confidential  Page 104  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
3. How would you describe the overall level of pain/swelling in joints other than neck, back, 
hips you have had? 
4. How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure? 
5. How would you describe the overall level of morning stiffness you have had from the 
time you wake up?  
6. How long does your morning stiffness last from the time you wake up?  
To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The resulting 0 to 10 number is added to the scores from questions 1 -4. The  resulting 0 to 50 score is divided by 5 to give a final 0 – [ADDRESS_1027767] suboptimal control of disease, and subjects with scores of 4 or greater are usually good candidates for either a change in their medical therapy or for enrollment in clinical trials evaluating new drug therapi[INVESTIGATOR_750619]. BASDAI is a quick and simple index (taking between 30 seconds and 2 minutes to complete.  

[COMPANY_001]  Confidential  Page 105  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
16.5 Appendix 5: Guidelines for administering the PRO 
questionnaires  
All questionnaires will be available, where possible, in the local languages of the participating 
countries. 
All questionnaires will be completed  on an electronic device  at the scheduled study visit prior 
to the subject seeing the investigator for any clinical assessment or evaluation. The subject 
should be given sufficient instruction, space, time and privacy to complete the questionnaire. The study coordinator should check the questionnaire for completeness and encourage the subject to complete any missing responses. A detailed training manual relating to the administrative procedures of  the questionnaires will be provided to the sites. 
Completed questionnaires will be reviewed and examined by [CONTACT_093], before the clinical examination, for responses that may indicate potential adverse events (AEs) or serious adverse events (SAEs).  The investigator should review not only the responses to the questions in the 
questionnaires, but also any unsolicited comments written by [CONTACT_423]. If AEs or SAEs are confirmed, then the physician must record the events. Investigators should not encourage the subjects to change the responses reported in the completed questionnaires. 
The language in which each of the questionnaires to be completed will also be captured the first 
time a questionnaire is administered.  
Before trial begin  
Study coordinators  should familiarize themselves with the PRO questionnaire(s) in the trial and 
identify any items where a subject’s response might highlight issues of potential concern. For example, one question in the SF -36 asks ‘How much of the time in the past [ADDRESS_1027768] you 
felt downhearted and blue?’ If a subject responds ‘most or all of the time’, then the study coordinator should inform the study investigator.  
Before completion  
1. Subjects should be provided with the correct questionnaire 
• at the appropriate visits, and  
• in the appropriate language 
2. Subjects should have adequate space and time to complete the questionnaires 
3. Questionnaire should be administered before the clinical examination  
During completion  
1. Administrator may clarify the questions but should not influence the response 

[COMPANY_001]  Confidential  Page 106  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
2. Only one response for each question 
3. Also see ‘Addressing Problems and Concerns’  
After completion  
1. Check for completeness and not for content* 
2. Check for multiple responses that were made in error**  
3. Data should be transcribed from the completed questionnaire to the appropriate web 
portal** 
4.  File completed questionnaire in the patient study files**  
* However, any response which may directly impact  or reflect the subject’s medical 
condition (e.g. noting of depression) should be communicated by [CONTACT_144978]).  
** Only applicable if a paper PRO questionnaire(s) is utilized as a backup should there be 
a failure with the elec tronic device.  
Addressing Problems and Concerns 
Occasionally a subject may have concerns or questions about the questionnaires administered. 
Guidance related to some of the most common concerns and questions are given below. 
The patient does not want to co mplete the questionnaire(s) 
Tell the subject that completion of the questionnaire(s) is voluntary. The goal is to better 
understand the physical, mental, and social health problems of subjects. Emphasize that this information is as important as any of the other medical information, and that the questionnaire(s) is simple to complete. Suggest that the questionnaire(s) may be different from anything the respondent has filled in the past. If the subject still declines, retrieve the questionnaires. Record the reason for the decline, and thank the subject. 
The patient is too ill or weak to complete the questionnaire(s)  
In these instances, the coordinator may obtain subject responses by [CONTACT_90222], followed by [CONTACT_750675], and entering the subject’s 
response. No help should be provided to the subject by [CONTACT_90224]. The coordinator should not influence subject responses. The study coordinator cannot translate the question into simpler language and has to be read verbatim.  
The patient wants someone else to complete the questionnaire(s)  
In no case should the coordinator or anyone other than the subject provide responses to the questions. Unless specified in the study protocol proxy data are not  an acceptable substitute for 
subject self -report. Subjects should be discouraged from asking a family member or friend for 
help in completing a questionnaire. 
The patient does not want to finish completing the questionnaire(s)  
If non- complet ion is a result of the subject having trouble understanding particular items, ask 
the subject to explain the difficulty. Re -read the question for them verbatim , but do not rephrase 
the question. If the respondent is still unable to complete the questionnai re, accept it as 
incomplete. Thank the subject. 
[COMPANY_001]  Confidential  Page 107  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
The patient is concerned that someone will look at his/her responses  
Emphasize that all responses are to be kept confidential. Point out that their names do not appear 
anywhere on the questionnaire, so that their results will be linked with an ID number and not their name. Tell the subject that his/her answers will be pooled with other subjects’ answers and that they will be analyzed as a group rather than as individuals. Tell the subje ct that completed 
forms are not routinely shared with treating staff, and that their responses will only be seen by [CONTACT_10825] (to check for completeness), and possibly the investigator. Any response which may directly impact on or reflect their medical condition  (e.g. noting of severe depression) will be 
communicated by [CONTACT_90226]. 
The patient asks the meaning of a question/item  
While completing the questionnaire, some subjects might ask the meaning of specific items so 
that they can better understand and respond. If this happens, assist the subject by [CONTACT_250374]. If the subject asks to interpret the meaning of an item, do not try to 
explain it, but suggest that he/she use his/her own interpretation of the question. Subjects should answer the questions based on what they  think the questions mean.  
General information about all questionnaire(s):  
All questionnaires have to be completed by [CONTACT_250375]. The questionnaires should be completed by [CONTACT_90227] a quiet area free from disturbance, and before any visit assessments. Patients should receive no help from family members; if questions cannot be answered alone (due to problems with reading or understanding), then the doctor or nurse should read the questions and record the patient’s responses without influencing their answers. The information provided is strictly confidential and will be treated as such. If a patient has missed a question or given more than one  response 
per question, then this should be brought to patient. Incomplete questions should not be accepted without first encouraging the patient to complete unanswered questions. 
The investigator must complete the patient/visit information on the electron ic device and ensure 
that the center number, patient’s number and initials are identical to the Case Record Form. As 
there are no source data for this questionnaire, the data queries will be restricted to patient/visit information. 
16.6 Appendix 6: Liver event and laboratory trigger definitions and 
follow -up requirements  
Table 16-3 Liver Events and Laboratory Trigger Definitions 
  Definition/ threshold  
LIVER LABORATORY TRIGGERS  [ADDRESS_1027769] < ALT / AST  ≤ [ADDRESS_1027770] < TBL  ≤ [ADDRESS_1027771] > 5 × ULN  
  ALP > 2 × ULN (in the absence of known bone 
pathology)  
  TBL > 2 × ULN (in the absence of known Gilbert 
syndrome)  
  ALT or AST > 3 × ULN and INR > 1.5  
[COMPANY_001]  Confidential  Page 108  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
  Potential Hy’s Law cases (defined as ALT or 
AST > 3 × ULN and TBL > 2 × ULN [mainly 
conjugated fraction] without notable increase in 
ALP to > 2 × ULN)  
  Any clinical event of jaundice (or equivalent 
term)  
  ALT or AST > 3 × ULN accompanied by 
(general) malaise, fatigue, abdominal pain, 
nausea, or vomiting, or rash with eosinophilia  
  Any adverse event potentially indicative of a liver 
toxicity *  
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-
related conditions; non- infectious hepatitis; benign, malignant and unspecified liver neoplasms  
TBL: total bilirubin; ULN: upper limit of normal  
Table 16-4 Follow up Requirements for Liver Events and Laboratory Triggers  
Criteria  Actions required  Follow -up monitoring  
Potential Hy’s Law casea Discontinue the study drug immediately  
Hospi[INVESTIGATOR_18552], if clinically appropriate  
Establish causality  
Complete appropriate eCRF 
pages  ALT, AST, TBL, Alb, PT/INR, ALP and γGT until resolution
c 
(frequency at investigator discretion)  
ALT or AST  
> 8 × ULN  Discontinue the study drug immediately  
Hospi[INVESTIGATOR_750620], AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc 
(frequency at investigator 
discretion)  
> 3 × ULN and INR > 1.[ADDRESS_1027772], TBL, Alb, PT/INR, ALP and γGT until resolution
c 
(frequency at investigator discretion)  
> 5 to ≤ 8 × ULN  Repeat LFT within [ADDRESS_1027773], TBL, Alb, PT/INR, 
ALP and γGT until resolutionc 
(frequency at investigator discretion)  
[COMPANY_001]  Confidential  Page 109  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Criteria  Actions required  Follow -up monitoring  
> 3 × ULN accompanied by 
[CONTACT_750676][INVESTIGATOR_750620], AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc 
(frequency at investigator 
discretion)  
> 3 to ≤ 5 × ULN  
(patient is  asymptomatic)  Repeat LFT within the next week  
If elevation is confirmed, initiate 
close observation of the patient  Investigator discretion  
Monitor LFT within 1 to 4 weeks  
ALP (isolated)      
> 2 × ULN (in the absence of known bone pathology)  Repeat LFT within 48 hours  
If elevation persists, establish causality  
Complete appropriate eCRF 
pages  Investigator discretion  
Monitor LFT within 1 to 4 weeks or at next visit  
TBL (isolated)      
> 2 × ULN (in the absence of known Gilbert syndrome)  Repeat LFT within [ADDRESS_1027774], TBL, Alb, PT/INR, 
ALP and γGT until resolutionc 
(frequency at investigator 
discretion)  
Test for hemolysis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> 1.5 to ≤ 2 × ULN  
(patient is asymptomatic)  Repeat LFT within the next week  
If elevation is confirmed, initiate 
close observation of the patient  Investigator discretion  
Monitor LFT within [ADDRESS_1027775], TBL, Alb, PT/INR, 
ALP and γGT until resolutionc 
(frequency at investigator 
discretion)  
Any AE potentially indicative of a liver toxicity*  Consider study drug interruption or discontinuation  
Hospi[INVESTIGATOR_750621]  
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-
related conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms  
[COMPANY_001]  Confidential  Page 110  
Clinical T rial Protocol (Version No. 00)   Protocol No. CAIN457P12301  
 
Criteria  Actions required  Follow -up monitoring  
TBL: total bilirubin; ULN: upper limit of normal  
a Elevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × 
ULN 
b (General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia  
c Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death.  
 